The global medication shortage has reached a record 323 shortages in 2024, affecting all drug classes, particularly sterile injectable generics.

Drug shortages, often caused by manufacturing and quality issues, can last over two years and affect over half a million patients.

International cooperation is necessary to combat epidemics and address global medication shortages during the pandemic.

The EU has proposed a mechanism to share medicines, set up an early warning system, and allowed stockpile access in emergencies.

The EU has established the Critical Medicines Alliance to address drug shortages.

Global health systems face shortages, highlighting the need for international collaborations.

The Ministry of Health has proposed strategies to address drug shortages, including alternative drugs and international collaborations.

International collaborations and investments in vaccine research have helped countries obtain necessary resources for epidemic prevention and reliable vaccines.

China has provided vaccines to 110 countries, supplied over 1.7 billion doses worldwide, and sent experts to 34 countries for epidemic aid.

The WHO and others have established the Pandemic Supply Chain Network to reduce disruptions during pandemics.

Partnerships and collaborations have reduced COVID-19 supply chain disruptions, with seven key actions recommended for global health security.

Geographical diversification and improved inventory management are necessary for health security.

Data exchange platforms require funding, and free trade reduces viral spread risk.

Strengthening health systems improves primary care, epidemic response, and universal health coverage.

International collaborations and agreements have shown that cooperation, data sharing, and transparency are key to addressing global medication shortages.

These lessons can be applied by establishing early warning systems, improving inventory management, and promoting geographical diversification.

Technology, like AI, can help match cancer patients with suitable treatments and alleviate the global healthcare staff shortage.

International collaborations can facilitate innovative clinical products and patient-centered care.

Establishing a drug shortage center and reviewing health insurance drug pricing can help address shortages.

International collaborations are crucial in addressing global medication shortages.

The global healthcare sector faces a severe workforce shortage, with a projected deficit of 10 million staff by 2030.

AI and ML are being applied to address medication shortages by creating operational efficiencies in pharmaceutical companies.

AI is being used in drug discovery to optimize development timelines and costs.

Aide Chemists uses AI to predict medication demand in Africa and improve health outcomes.

The company has partnered with Causal Foundry to optimize its supply chain and make medicines more affordable using AI.

AI can deepen biology understanding and speed up new drug discovery, helping address medication shortages.

AI in precision medicine improves care quality and safety through personalized analysis of patient data.

AI tools predict patient allergy risks to certain antibiotics, reducing costs and adverse effects.

The global AI medical market is expected to grow from $4.9 billion in 2020 to $45.2 billion by 2026.

The AI market growth is driven by the shortage of medical resources due to an aging population.

Omnicell provides medication automation solutions to over 50,000 North American pharmacies.

Drug shortages cost facilities at least $359 million annually, affecting 99% of hospitals.

The FDA is allowing imports and hospitals are rationing or offering alternatives to address chemotherapy drug shortages.

AI and big data are improving drug R&D design and efficiency, including predicting protein structure.

India's AI in drug discovery market is expected to reach INR 2.57 trillion by 2028.

Stringent regulations are hindering AI integration in India's market, but AI technologies are transforming pharmaceutical research and development.

AI and ML are being applied to address medication shortages by improving operational efficiencies and optimizing development.

The effectiveness of solutions to address medication shortages is being evaluated using metrics such as the number of drugs in shortage, duration, and impact on patient care.

Quality metrics, including defect rates, customer satisfaction, and on-time delivery, assess the performance of solutions to address medication shortages.

The Drug Deficiency Database tracks medication shortages, providing data on their scope and impact.

The Ministry of Industry and Trade tracks metrics like withdrawn medicines, citizen complaints, and expired drug sales to evaluate solution effectiveness.

Key performance indicators (KPIs) are established to evaluate outsourced services through communication, site visits, audits, and performance reviews.

Quality management tools provide real-time data to enable prompt issue resolution and quality improvement decisions.

Benchmarking and corrective action processes ensure effective and efficient solutions to medication shortages.

The FDA blames supply chain gaps and downtime for shortages, citing a need for better metrics.

Lack of transparency hinders response to drug shortages, making it essential to track metrics like the number and duration of shortages.

The average shortage affects at least half a million patients, highlighting the need for effective solutions.

Medication shortages cost facilities at least $359 million per year.

Drug use evaluation is a key component of pharmacy quality management, aiming to improve care quality and prevent adverse interactions.

A unit evaluates drug use against predefined criteria, measuring effectiveness and correcting non-conforming usage patterns.

The Ministry of Health and Prevention has launched an AI center of excellence for strategic drug inventory management and tracking medicine shipments.

AI is used to analyze birth and death data to understand causes and make informed decisions.

Predictive analytics and AI can mitigate and solve supply chain difficulties.

Cloud-based tools and data approaches leverage analytics investments for planning and forecasting.

Low-code and no-code platforms increase efficiency and create personalized customer experiences without surveillance.

AI optimizes content delivery for hyper-personalization, benefiting industries like finance and healthcare.

In 2024, 323 US drugs, mostly non-patented sterile injectables, faced shortages.

Chemotherapy and ADHD drugs were among those affected by shortages.

Lilly increased Mounjaro production, but US drug shortages worsened since 2021 due to supply chain issues.

The White House proposed $3.26-5.11 billion to address drug shortages, which the FDA currently tracks through manufacturer phone calls.

Covid-19 has accelerated company digitization 20-25 times, except in biotech and pharma, which are hindered by regulatory requirements.

Edge computing and smart manufacturing enhance equipment digitally, including temperature monitoring of shipments.

Digital transformation involves rethinking processes using artificial intelligence and machine learning to inform decision-making.

AI is used in supply chain management and healthcare for automation, predictive analysis, disease detection, and patient flow management.

Medikabazaar delivered 10,000 oxygen concentrators during COVID-19 and uses AI for precise medical supply stock projections.

Medikabazaar's platform hosts over 700,000 medical device SKUs, reducing hospital operational expenses by up to 30 percent through automation.

VIZI AI-ML based inventory management system will improve India's medical supply chain and availability with CDC's investment.

Predictive analytics and digital supply chain management reduce inventory by 22% and costs by 10-15%.

Big data analytics and digital transformation aid customer acquisition and increase operational efficiency by 20%.

Automation and digital tools improve efficiency by 20% and streamline workflows by 30%.

The global medication shortage has reached a record 323 shortages in 2024, affecting all drug classes, particularly sterile injectable generics.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

Drug shortages, often caused by manufacturing and quality issues, can last over two years and affect over half a million patients.

International cooperation is necessary to combat epidemics and address global medication shortages during the pandemic.

Title:

Content: Corona
Corona for the third year...
Health Life and Development
Corona for the third year
Health Life and Development
With the beginning of the third year, the new Coronavirus continues to mutate, maneuver, elude and spread rapidly, which has increased the burden on health systems, including strong systems in their infrastructure, medical, technical and administrative staff and financial capabilities, and made them resist with difficulty in continuing to perform their tasks.
Not to mention the fragile and weak health systems, which suffer from a lack of resources, funding and cadres, with the burdens of treatment services for chronic diseases, and the lack or absence of preventive services programs and immunization programs against infectious and communicable diseases.
As the pandemic continues for the third year in a row, this has directly affected the possibilities available to all health systems with their diversity, and to health workers in general and on the front lines of the pandemic in particular.
The health sector in the world has lost large numbers of workers due to the infection of the virus, with the negative psychological and social effects suffered by most health workers under the continuous pressure for the third year in a row, and due to a clear imbalance between the countries of the North and South in the fields of scientific and medical research in the development of preventive, diagnostic and therapeutic protocols. While immunization rates have increased in some countries and reached nearly 90% of the target groups, the largest proportion of countries, especially poor countries and low-income countries, still remain at low rates not exceeding 10% of the target groups at best, as industrialized countries suffer from the ability to absorb the increasing numbers of infected.
Hospitals are not enough and are not equipped with ventilators and suffer from a severe shortage of medicines, supplies and trained staff, which necessitates the search for alternative and effective treatment solutions with the belief that the virus may not be the same in all geographical regions and epidemics are transnational in nature. These deadly epidemics affect health, social, human and economic life.
It also requires all national health systems to review their organizational structures and prioritize them, identify the required capabilities and allocate the necessary financial and human resources to ensure the ability of health systems to cope with pandemics, provide services that enhance community health, develop primary health care programs, and continue to provide advanced therapeutic services at all levels of the health system.
Due to the difficult circumstances experienced by communities and countries under epidemiological conditions, it is necessary to review the laws and health legislation that define the authorities, rights and duties and the role of responsible institutions in dealing with health crises, most importantly epidemics and pandemics, to ensure that precautionary measures are identified, followed up and applied. Or the economy.
And the need to intensify, encourage and support medical, social, humanitarian and economic research to develop the necessary policies and procedures for social, humanitarian and economic protection and develop treatments by scientific and practical means and methods and support them with clinical and laboratory studies and adopt preventive, diagnostic and therapeutic protocols and develop them in line with epidemiological conditions and the impact of vaccines with the spread of viruses and their ability to raise immunity The equipment required to give vaccinations and prepare the necessary cadres.
The role of precautionary measures in reducing injuries and the effectiveness of non-drug interventions such as wearing a mask, physical distance and staying at home and their health and social effects related to their role in the regional context in terms of accepting the idea of isolation or not and developing strategies, plans and programs to achieve health protection for the population, communities and peoples and social protection psychologically and economically. Unification of research efforts in the same country between centers, institutes, research bodies, universities and the health sector with all its components and joint cooperation between them and the region similar to its countries in social, health, environmental and health conditions and health systems
The need for concerted efforts around the world to develop effective diagnostics and treatment methods, develop safe and effective vaccines to protect against viruses and their rapid mutations, and ensure justice in their distribution without discrimination between countries and peoples, and enable and support all countries capable of manufacturing vaccines.
The need to intensify local efforts and provide the necessary capabilities with regional and international cooperation in supporting local and international efforts in combating epidemics because everyone is concerned with the global health crisis and the resulting economic, social and development crises.
The global epidemic is in dire need of concerted international efforts and support for scientific research and studies.
Directing human cadres to learn and train, harnessing all the necessary capabilities, fair distribution of medicines and vaccines, exchange of information between the competent authorities in all countries of the world, and development of legislation and health laws in line with the health crises and their effects and all support for the health sector and its workers.
Societies need economic, social and psychological support to survive with minimal damage.
God saved humanity and the world from the epidemic
I'm sorry.
Congratulations to Abougren.
Member of the Executive Council of the Union of Arab Hospitals
Member of the Technical Advisory Committee of the Council of Arab Ministers of Health
Related Articles
Go to the top button

The EU has proposed a mechanism to share medicines, set up an early warning system, and allowed stockpile access in emergencies.

Title:

Content: Brussels is planning for EU countries to share vital medicines and take emergency measures to avoid a repeat of shortages that hit the bloc a year ago.

The European Commission is proposing a “voluntary solidarity mechanism” requested by France and Germany and an early warning system flagging when drugs become scarce, according to draft proposals seen by the Financial Times. If insufficient donors come forward, EU capitals will be allowed to tap into an EU-funded stockpile set up during the Covid-19 pandemic and take other emergency measures.

In December and January western countries suffered a shortage of antibiotics including penicillin and amoxicillin, and painkillers such as paracetamol, especially in medicines used by children.

Among the emergency measures floated to prevent a repeat of that crisis, the commission could allow the extension of a drug’s shelf life, fast track approvals of alternative suppliers and support production increases.

Brussels will also encourage joint procurement of drugs from 2024 and medicine swaps with countries in the southern hemisphere, where peak winter demand happens at a different time.

The commission will draw up guidance for national stockpiles in 2024 and establish a Critical Medicines Alliance bringing governments, industry and civil society together. The commission declined to comment.

Three-quarters of countries reported a worsening of drug shortages in 2022, according to an industry survey. EU manufacturing is heavily reliant on imported active pharmaceutical ingredients from China and India.

Rising demand and disruption to supply chains have been compounded by inflation hitting the production of generic drugs, which typically sell at much lower prices than branded versions.

France has been actively encouraging the reshoring of basic medicine supply, with a giant paracetamol factory set to open in the country next year.

The EU is discussing whether to provide more funding for domestic production.

The commission’s proposal is scheduled to be approved on October 25 and could still change. Initially non-binding, it could lead to a Critical Medicines Act, with Brussels drawing up a list of vital medicines by year-end.

The commission also urges member states and the European parliament to approve its overhaul of pharmaceutical legislation, put forward in April. It includes plans to take control of drug production in the event of a public health emergency, a requirement for stockholders to inform Brussels of supply levels and for manufacturers to give early warnings of shortages.

An analysis by the European Medicines Agency and the commission found that unless there is unexpected demand the EU should avoid an antibiotics shortage this year.

“The information available today suggests that — if demand in the coming winter season does not differ significantly from the demand of recent years — the supply to the EU of key antibiotics seems to generally match demand,” the analysis said.

“However, this depends strongly on the compliance of industry with their legal obligations to ensure supply and their ability to adapt.”

Copyright The Financial Times Limited 2023. All rights reserved.
Reuse this content (opens in new window) CommentsJump to comments section

Follow the topics in this article

The EU has established the Critical Medicines Alliance to address drug shortages.

Title:

Content: Brussels is planning for EU countries to share vital medicines and take emergency measures to avoid a repeat of shortages that hit the bloc a year ago.

The European Commission is proposing a “voluntary solidarity mechanism” requested by France and Germany and an early warning system flagging when drugs become scarce, according to draft proposals seen by the Financial Times. If insufficient donors come forward, EU capitals will be allowed to tap into an EU-funded stockpile set up during the Covid-19 pandemic and take other emergency measures.

In December and January western countries suffered a shortage of antibiotics including penicillin and amoxicillin, and painkillers such as paracetamol, especially in medicines used by children.

Among the emergency measures floated to prevent a repeat of that crisis, the commission could allow the extension of a drug’s shelf life, fast track approvals of alternative suppliers and support production increases.

Brussels will also encourage joint procurement of drugs from 2024 and medicine swaps with countries in the southern hemisphere, where peak winter demand happens at a different time.

The commission will draw up guidance for national stockpiles in 2024 and establish a Critical Medicines Alliance bringing governments, industry and civil society together. The commission declined to comment.

Three-quarters of countries reported a worsening of drug shortages in 2022, according to an industry survey. EU manufacturing is heavily reliant on imported active pharmaceutical ingredients from China and India.

Rising demand and disruption to supply chains have been compounded by inflation hitting the production of generic drugs, which typically sell at much lower prices than branded versions.

France has been actively encouraging the reshoring of basic medicine supply, with a giant paracetamol factory set to open in the country next year.

The EU is discussing whether to provide more funding for domestic production.

The commission’s proposal is scheduled to be approved on October 25 and could still change. Initially non-binding, it could lead to a Critical Medicines Act, with Brussels drawing up a list of vital medicines by year-end.

The commission also urges member states and the European parliament to approve its overhaul of pharmaceutical legislation, put forward in April. It includes plans to take control of drug production in the event of a public health emergency, a requirement for stockholders to inform Brussels of supply levels and for manufacturers to give early warnings of shortages.

An analysis by the European Medicines Agency and the commission found that unless there is unexpected demand the EU should avoid an antibiotics shortage this year.

“The information available today suggests that — if demand in the coming winter season does not differ significantly from the demand of recent years — the supply to the EU of key antibiotics seems to generally match demand,” the analysis said.

“However, this depends strongly on the compliance of industry with their legal obligations to ensure supply and their ability to adapt.”

Copyright The Financial Times Limited 2023. All rights reserved.
Reuse this content (opens in new window) CommentsJump to comments section

Follow the topics in this article

Global health systems face shortages, highlighting the need for international collaborations.

The Ministry of Health has proposed strategies to address drug shortages, including alternative drugs and international collaborations.

Title:

Content: The lack of medicine continues to burn!
The Ministry of Health and Welfare has proposed a short, medium and long-term strategy to deal with the current 5 coping mechanisms.
Journalist Yen Zhenzhen / Taipei Report
According to the Ministry of Health and Welfare, the shortage of drugs is not a single factor, but includes supply problems, manufacturing problems, clinical demand factors, uneven distribution of drugs, drug use habits and drug prices. In addition to dealing with the relatively high clinical demand items, it is properly allocated to all levels of medical institutions and pharmacies to fully meet the needs of clinical end-use drugs.
This is an advertisement, please continue reading.
In the face of the shortage of drugs, Wang said, the existing health insurance uses five major coping mechanisms, including 1, a single processing window, a dedicated person to help deal with the problem of drug purchase, and contact the Food and Drug Administration to put relevant information on the website of the NHI. (4) Drug price adjustment mechanism that does not meet the cost can be re-checked according to the way of raising the price of special drugs; (5) Alternative drugs can still declare the cost, if they are not irreplaceable, they can be replaced at the same price or lower than the original prescription drug price.
In addition, Wang pointed out that in the face of the international epidemic, the Russian-Ukrainian war, and labor shortage, drug shortage is a problem facing all countries. In order to strengthen the stable supply mechanism of drugs in China, the Ministry of Health and Welfare continues to actively respond to the short-term strategy to solve the problem of drug shortage. The Food and Drug Administration (FDA) and the pharmaceutical industry have made every effort to actively arrange production lines, strive for early import, increase production / import quantity, and properly distribute to all levels of medical institutions and pharmacies to fully meet the demand for clinical end use drugs.
In addition, to properly handle the issue of drug price adjustment, the Central Health Insurance Administration of the Ministry of Health and Welfare intends to implement the "Universal Health Insurance Cost Distribution Target System (DET)" in April this year, which will adjust the number of drug prices and adjust the quota in a suitable manner, taking into account factors such as the epidemic, the Russian-Ukrainian war and inflation.
In terms of medium-term strategy, Wang said that he will establish a permanent drug shortage treatment center and optimize drug supply information transmission.
In order to speed up the handling of drug shortage incidents, we will adopt dedicated personnel and cross-departmental cooperation to develop drug shortage prevention policies to prevent drug shortage in advance, strengthen cross-departmental data integration and proactive monitoring to detect drug shortage incidents at an early stage, and intervene early through cross-departmental cooperation to stabilize drug supply.
At the same time, the Food and Drug Administration (FDA) continues to disseminate drug supply and alternative drug information through various channels. In addition to posting on the “Drug Supply Information Platform ”, the FDA will notify medical institutions and pharmacies through VPN, and weekly letters to relevant medical associations and public associations to inform members. Management system.
In the long-term strategy section, it includes reviewing the current health insurance drug pricing policy and encouraging the production of domestically manufactured generic drugs.
Wang Bi-sheng pointed out that in the review of the current health insurance drug price policy, including the development of the price protection of indicative drugs, drug price review for the lack of drugs; start the review of drug expenditure target (DET), plan the establishment of a risk control mechanism, plan the national unified procurement trial plan; comprehensively review the health insurance drug price policy, give an appropriate price protection mechanism for necessary drugs, and also target the patent period. To encourage the production of domestic manufacturers to ensure that when there is a shortage of original pharmaceutical products, there are domestic famous drugs to respond.
Wang also stressed that the Food and Drug Administration has set up a "Drug Supply Information Platform" (https: / / dsms.fda.gov.tw /), reporting hotline (02) 27878249. If medical institutions and pharmacies have any shortage of drugs, they can go to the platform for enquiry or notification, and the department will deal with it immediately.
This is an advertisement, please continue reading.

International collaborations and investments in vaccine research have helped countries obtain necessary resources for epidemic prevention and reliable vaccines.

Title:

Content: Editorial: Preparing for the Next Pandemic
Font Size:
The Ministry of Health established the Epidemic Preparedness and Response Research Project (PREPARE) to build a more robust infrastructure to combat the spread of epidemics.
The National Center for Infectious Diseases was established after the SARS epidemic in 2003, and China has once again learned lessons and strengthened the overall health care system.
The goal of the project is to improve China's scientific research capabilities in the next five years, while rapidly transforming the research results into effective anti-epidemic tools and products.
The scope of research covers five areas: data analysis and modeling of infectious diseases and social behavior, environmental transmission mechanisms and prevention and control, diagnosis, research and development of vaccines and drugs, and the expansion of regional cooperation networks.
With the intensification of climate change and the acceleration of the world ’ s population movement, the threat to humanity posed by the evolution and development of coronavirus and other new viruses is becoming more and more inescapable.
Over the past three years, humanity has witnessed multiple failures in the fight against mass epidemics, resulting in serious human casualties and economic losses, leaving indelible scars on society and the psychology of the population.
Therefore, at this moment when the epidemic continues to slow down, it is time to review how to actively prepare for the next pandemic or other deadly diseases in terms of software and hardware.
At the launching ceremony held last week, Professor Wang Linfa, director of the research project, admitted that the response to the epidemic over the past two years shows that China's existing mechanisms are still inadequate.
The new mechanism will be able to integrate data as soon as possible, providing scientific expertise and technical specifications for government decision-making, such as details such as masks, disinfectant use and ventilation requirements.
"In the future, we will have to master the mode of transmission of the virus within one month and develop a rapid detection method within 100 days," he said.
According to experts, Singapore needs to be fast enough to respond to the epidemic, while considering the protection of privacy, the two must strike a balance; in addition, China's eight third-level biosafety laboratories have failed to deal with dangerous pathogens, including testing and developing vaccines.
The NUDT ’ s existing biosafety Level 3 laboratory, which will be operational in 2025, will be upgraded to the highest level 4, and will be able to deal more effectively with the more deadly level 4 pathogens as well as possible future biological threats.
In the early days of the fight against the coronavirus, China's network of contacts in the international medical and trade fields played a major role in ensuring that the latest information is kept abreast, and the necessary resources for epidemic prevention are obtained, to the maximum extent possible, and decisions are made according to the evolution of the virus.
In addition, multi-investment in vaccine research and development units and enterprises has also ensured that we can obtain the most reliable vaccine in the first time to help Chinese people fight the epidemic and save their lives.
As can be seen from the development of the international epidemic, countries that lack preparation and resources have been hit hard.
The experience of the coronavirus pandemic shows that biomedicine is a strategic industry of a country, and should not be overlooked, just as the US government recognizes the importance of chip production capacity to maintain the national development lifeline, and begins to intervene in resources and policies.
In the past two years, China has successfully won more international pharmaceutical manufacturers to come to invest, they can provide advanced production capacity of medical materials, but also have R & D personnel, which is important for the establishment of local medical-related ecological circle, which will help China's experts to integrate and deeply build epidemic protection infrastructure before the next wave of pandemics.
The gathering of large international manufacturers and talents will benefit our future bargaining power for some drugs, enhance our advantages, and in times of crisis, not only save ourselves but also save others – for example, ensure that countries in the region can also get timely supplies.
Therefore, it is important for the government to actively intervene and continue to strengthen the R & D capacity of this key industry.
The new program will also be able to pre-empt the evolution of some of the different viruses, speed up the development of drugs or vaccines if necessary, and train more local personnel to guard the country.
The key to winning the next pandemic war is to continue to expand China's existing strong international network, including scientific research, health, trade and even diplomatic networks, and to eliminate unnecessary administrative procedures and develop more effective coping mechanisms at home.
The continuous improvement of state institutions and the planning of more advanced mechanisms in accordance with scientific rationality can not only achieve the professional goal of protecting human life, but also further strengthen the confidence of the people in the system.
On the other hand, after the past three years, people should also improve themselves in terms of life and health culture, so as not to "live up to" this long epidemic.
LIKE Our official website for more information

China has provided vaccines to 110 countries, supplied over 1.7 billion doses worldwide, and sent experts to 34 countries for epidemic aid.

Title:

Content: People 's Network > > International
China makes positive contribution to global solidarity against COVID-19 (expert interpretation)
■ Interviewee expert: Zhou Taidong, China International Development Knowledge Center
November 22, 2021 19: 26 | Source: People's Daily Overseas Edition
Small number
On November 17, the seventh batch of COVID-19 vaccines from China arrived at the Phnom Penh International Airport in Cambodia, and the Cambodian government held a grand welcoming ceremony.
The picture shows staff transporting the Chinese COVID-19 vaccine at the airport.
Photo by Pi Long (Xinhua)
On November 10, the Economist think tank of the British "Economist" magazine released a report that as of the end of October, the world has been vaccinated with more than 7 billion doses of vaccines, driven by the Chinese vaccine, Chile and Cambodia vaccination rates have reached 79%, 77%, higher than the United States and Europe and other developed countries.
“Vaccines in China are expected to be a lifeline for developing countries. ”
The New York Times commented that since the outbreak of the new coronavirus epidemic, China has been committed to making the new coronavirus vaccine a global public product and promoting the accessibility and affordability of vaccines in developing countries.
Since the outbreak of the epidemic, China has always adhered to the concept of a community with a shared future for mankind, stood by the international community to help each other and overcome the difficulties, took the lead in proposing the establishment of a human health community, pooled the consensus of the international community on anti-epidemic cooperation, and actively promoted international anti-epidemic cooperation with practical actions to make positive contributions to global solidarity.
First, China has provided material assistance to more than 150 countries and 13 international organizations in the fields of masks, protective clothing, ventilators, oxygen cylinders, nucleic acid testing reagents and testing equipment; second, it has sent 37 expert groups to 34 countries and organized nearly 1,000 technical guidance sessions; third, it has shared its anti-epidemic experience with other countries through video exchanges. Provide cash assistance to international organizations, including the World Health Organization and the United Nations and other relevant international organizations totaling $100 million; Fifth, implement the commitment to make vaccines a global public good, so far to 110 countries and international organizations have provided more than 1.7 billion doses of vaccines, ranking first in the world.
Compared with developed countries, China ’ s international cooperation in fighting the epidemic has remarkable characteristics.
First, it is urgent to show China's speed.
Emergency assistance adopts the strategy of "urgent affairs, special affairs and special affairs".
At the end of April this year, the Delta mutant virus caused a sharp rebound in the epidemic in China's neighboring countries in South and Southeast Asia.
Within a few days, China also coordinated the dispatch of medical experts to Laos.
Second, both hardware and software assistance.
In addition to providing various medical supplies, vaccines and sending medical experts, China has also helped countries fight the epidemic by holding video experience exchanges and setting up a stockpile of anti-epidemic materials in South Asia.
The Chinese side has overcome the difficulties of the epidemic, started ahead of schedule the construction of the headquarters of the African CDC in Addis Ababa, capital of Ethiopia, and used practical actions to jointly build the China-Africa Health Community.
Third, uphold fairness and justice and promote fair distribution of vaccines.
China firmly adheres to the "first attribute" of global public products of vaccines, and supplies vaccines to the world at a time when its own demand is huge and the supply of vaccines is very tight.
In October last year, China officially joined the COVID-19 Vaccine Implementation Plan (COVAX).
From Southeast Asia to Latin America to Africa, the Chinese vaccine is the first vaccine obtained in many developing countries.
These countries vividly refer to Chinese vaccines as "timely rain."
In order to make greater efforts to ease the shortage of global vaccine supply, China has insisted on "giving people fish" and "giving people fish", and has built or is building vaccine stock filling bases in 15 countries, creating local vaccine production centers, and actively supporting the exemption of COVID-19 vaccine intellectual property rights to developing countries.
In addition, China launched the "Belt and Road" vaccine partnership initiative involving 31 countries, held an international forum on vaccine cooperation, and promoted the international community to build a cooperation mechanism with vaccine companies.
China has taken concrete actions to build a solid immune barrier for the world, and has played an important role in leading international cooperation in the fight against the pandemic.
Looking to the future, China will continue to implement its commitment, and will strive to provide 2 billion doses of vaccines to the world in 2021, donate 100 million doses of vaccines to developing countries free of charge, and donate 100 million dollars to the COVID-19 Vaccine Implementation Plan.
China will continue to lead global anti-epidemic cooperation and economic recovery, promote the establishment of a human health community, promote the Global Development Initiative, and work together with other countries to achieve economic recovery and common prosperity.
(This reporter Jia ordinary interview collated)
(Edited by: Hao Jiangzhen, Yuan Bo)
Share it so more people can see it.
Back to top

The WHO and others have established the Pandemic Supply Chain Network to reduce disruptions during pandemics.

Title:

Content: 7 essentials to create a resilient global healthcare supply chain

  • SARS, Ebola and COVID-19 have tested the world’s ability to deal with outbreaks and pandemics.
  • A global pandemic preparedness system needs sustained political will and investment to ensure the global healthcare supply chain can effectively respond to a crisis.
  • If we don’t get serious about pandemic preparedness now, millions more lives will be at stake.

It was 20 years ago, when the SARS outbreak exposed key fragilities in the global healthcare supply chain, that people internationally began to talk seriously about pandemic preparedness.

Eight years ago, when the Ebola outbreak proved the world no better prepared to address outbreaks, there was more talk and some action. This included the founding of the Pandemic Supply Chain Network (PSCN), by the World Health Organization, World Economic Forum, World Bank, World Food Programme, US Centers for Disease Control and Prevention, Henry Schein and more than 60 companies. The PSCN was established to make it easier to anticipate and respond to global healthcare supply chain disruptions.

Yet today, nearly three years into the COVID-19 pandemic – the worst global health crisis in a century – many of the same supply-chain fragilities remain. Although partnerships, such as the PSCN, and national efforts somewhat blunted the severity of supply chain disruptions during the pandemic, the effort to develop a global pandemic preparedness system has yet to garner the sustained political will and investment needed to ensure that the global healthcare supply chain can effectively respond to a crisis.

3. Improved stockpiles and inventory management

In addition to enhancing stockpiles of personal protective equipment (PPE) at the local, regional and national levels, we must manage inventory more intelligently – from cycling inventory to deal with product expiry to coordinating and harmonising responses across jurisdictions.

4. Platforms for data sharing and enhanced transparency

Through the globally-focused PSCN and various national efforts, including the US Supply Chain Control Tower, Henry Schein has been working across sectors to support the creation of market intelligence platforms that enable the appropriate sharing of real-time supply chain data. While progress has been made, encouraging responsible information sharing across public and private partners requires significant additional funding.

5. Fostering the free flow of goods

Over the past three years, government restrictions on exports played a significant role in exacerbating product distribution shortages. While the desire of governments to protect their populations in times of crisis is understandable, international cooperation to allow the free flow of key products lessens the risk of panic buying, hoarding and, ultimately, viral spread.

6. Coordinated early-warning system for outbreaks

Detecting the next outbreak early is essential to mitigating its impact, protecting global healthcare supply chains and saving lives. Strengthening our global surveillance capacity requires significant investment and better coordination across governments, international organizations and the private sector.

7. Strengthened health systems and better primary care

As Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, famously said: “Universal health coverage and health emergencies are cousins — two sides of the same coin.” Major and sustained investment is needed if we are to reap the benefits of expanded access to care.

Let’s conclude with another number: one. This is the number of viruses it could take to shut down our world again. If ever there was an issue to unite us – one for which we all share the same risk – pandemic preparedness is it. If we don’t get serious now, millions more lives are surely at stake.

We are committed to Africa

Unlike many global publications, for nearly a decade we have been committed to showing a complete picture of Africa – not just a single story.  Offended by one-sided coverage of wars, disasters and disease, the founders of Africa.com created a website that provides a balanced view of Africa – current events, business, arts & culture, travel, fashion, sports, information, development, and more.

Will you support us?

Partnerships and collaborations have reduced COVID-19 supply chain disruptions, with seven key actions recommended for global health security.

Title:

Content: This came in a panel discussion held during the Forum – which was broadcast on its official website a little while ago – and highlighted that the global pandemic preparedness system needs sustained political will and investments to ensure that the global healthcare supply chain responds effectively to any crisis.
If we don ’ t take pandemic preparedness seriously now, the lives of millions more will be at stake.
The SARS, Ebola and COVID-19 crises have tested the world ’ s ability to deal with outbreaks of epidemics and infectious diseases, and the global pandemic preparedness system needs sustained political will and investments to ensure that the global healthcare supply chain responds effectively to the crisis.
“Eight years ago, when the Ebola outbreak proved that the world was no better prepared for outbreaks, there was more talk and some action, ” participants said.
This included the establishment of the Epidemiological Supply Chain Network (PSCN), by the World Health Organization, the World Economic Forum, the World Bank, the World Food Programme, the US Centers for Disease Control and Prevention and more than 60 companies.
However, nearly three years after the COVID-19 pandemic – the worst global health crisis in a century – many of the same supply chain vulnerabilities remain, and although partnerships, such as PSCN and national efforts have somewhat reduced the severity of supply chain disruptions during the epidemic, efforts to develop a global pandemic preparedness system have not yet mobilized the will. “The sustainable policy and investment needed to ensure that global health care is delivered in a way that can respond effectively to any crisis. ”
The Forum recommended seven key actions to address this issue:
- Providing political will and sustainable financing.
Although crises often lead to an influx of short-term spending, money quickly dries up as memories fade and priorities change.
Genuine global health security requires global financing mechanisms that enable sustainable investment and ultimately break panic and fear.
- Geographical diversification in manufacturing; achieving greater geographical diversity requires more than just investing in new factories.
Long-term contracts and financial guarantees are needed to maintain the manufacturing of important health-care materials in diverse locations.
- Improved inventory management.
In addition to strengthening stocks of personal protective equipment (PPE) at local, regional and national levels, we must manage medical stocks more intelligently.
- Establish platforms for data exchange and enhanced transparency.
Through globally focused PSCN and various national efforts, while progress has been made, encouraging responsible information sharing between public and private partners requires substantial additional funding.
Promote the free flow of goods.
Over the past three years, government restrictions on exports have played an important role in exacerbating the lack of product distribution.
While governments ’ desire to protect their people in times of crisis is understandable, international cooperation to allow the free flow of key products reduces the risk of viral spread.
- Strengthen coordinated early warning systems for epidemics.
Strengthening health systems and improving primary care.
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, said: “Universal health coverage and health emergencies are cousins – two sides of the same coin.
Significant and sustained investments are needed if we are to reap the benefits of expanded access to care. ”

Geographical diversification and improved inventory management are necessary for health security.

Data exchange platforms require funding, and free trade reduces viral spread risk.

Strengthening health systems improves primary care, epidemic response, and universal health coverage.

International collaborations and agreements have shown that cooperation, data sharing, and transparency are key to addressing global medication shortages.

These lessons can be applied by establishing early warning systems, improving inventory management, and promoting geographical diversification.

Technology, like AI, can help match cancer patients with suitable treatments and alleviate the global healthcare staff shortage.

Title:

Content: HKSTP collaborates with Glendale Hospital to pair cancer patients with innovative technology
Contract 00: 00 2023 / 06 / 21
Share:
Share:
The Hong Kong Science and Technology Parks Corporation (HKSTP) has been committed to promoting the clinical application of medical technology through the “Medical Technology Co-Innovation Platform ” programme to enhance the quality of care services.
HKSTP has recently signed a collaboration agreement with Courtyard Hong Kong Hospital to develop innovative clinical products and services to enhance patient care.
Hong Kong Science and Technology Parks Corporation and Hong Kong Courtyard Hospital signed a cooperation agreement, and the park company Codex Gene will use artificial intelligence medical solution matching platform to match suitable treatment options for cancer patients.
"There are now more than 210 park companies and incubators engaged in biomedical technology in the Science Park ecosystem, and they have considerable strength in translational research," said Mr Wong Ke-keung, Chief Executive Officer of Science Park.
Through the matching of Glendale Hospital and Park companies, the Science Park will open up more co-creation opportunities to promote the integration and wide application of scientific research results with clinical services. "
Mr Wong Ke-keung (left), Chief Executive Officer of the HKSTP, believes that the HKSTP will open up more opportunities for co-creation and facilitate the integration and wide application of research results with clinical services.
In the framework of the cooperation between the Science Park and Courtyard Hospital, Codex Genetics, a park company, will cooperate with Courtyard Hospital to provide suitable treatment options for cancer patients with an artificial intelligence (AI) -led medical solution matching platform.
“This collaboration is mainly focused on precision medicine. In the past, the company has been working with different hospitals to assist in the accurate treatment of lung cancer patients, and the cooperation with Granville Hospital is mainly focused on the more complex colorectal cancer types. ” The platform can accurately match the appropriate target drugs or new drugs for the patients ’ genetic characteristics after analyzing clinical tests and large data.
The Chief Executive of Coldplay, Mr Yim Kee-yuen, said that the collaboration with the Hong Kong Courtyard Hospital was mainly focused on the more complex type of colorectal cancer.
To raise the level of medical care and cultivate professional medical staff
“We are delighted to partner with the Hong Kong Science and Technology Park to connect our hospital with Asia ’ s most vibrant health technology and biotechnology innovation community. ” He hopes that medical technology can alleviate the global shortage of healthcare staff, and at the same time provide a new starting point for Hong Kong ’ s healthcare industry. To reduce the burden on patients and society.
The CEO of Glendale Hospital, Mr John Tsang, hopes that medical technology can alleviate the global shortage of medical staff and at the same time start a new starting point for medical care in Hong Kong.
Mr Tsang added that as the leading private teaching hospital in Hong Kong, the hospital has been committed to nurturing professional health care staff and upgrading the clinical and medical research standards in Hong Kong.
The project will include teaching research and data collection. We will also explore and expand cooperation areas such as managing health records with HKH and HKUST to turn more medical technologies into effective clinical treatment solutions. At the same time, we will “keep medical students abreast of the latest developments in the industry so that they can see the trends and changes in the future. ”
Create a platform for medical technology cooperation
The collaboration was facilitated by the Science Park ’ s “Medical Technology Co-Innovation Platform ” project. Courtyard Hospital was the first hospital to sign a cooperation agreement with the Science Park.
With the support of the platform, the two sides held their first meeting early last year and designated precision oncology as a preliminary research area.
After that, the HKSTP arranged for many rounds of matching between Hong Kong Courtyard Hospital and park companies focusing on this field, which eventually led to the successful cooperation between the hospital and Codex.
Liu Siya, Senior Director of the Research and Development Institute for Transformation of Science and Technology Parks, said that the cooperation could further accelerate the transformation of biomedical technology: “In the entire biomedical transformation process from innovative ideas to research and development, and launch into the market, the Medical Technology Co-Innovation Platform plays a key role in the final stage of application. ”
According to Liu Si-ya, senior director of the Institute of Transformation and Research at the Science and Technology Parks Corporation, the collaboration could further accelerate the transformation of biomedical technology.
“Through this initiative, we have established links between leading medical institutions, including Courtyard Hong Kong Hospital, and developers of innovative technologies to create clinical solutions.
Our ecosystem has a number of well-developed medical technologies that are suitable for clinical integration.
In addition, the program provides an open platform for health care professionals to explore and research different technologies, or to create more solutions with our partner companies to improve patient-centered integrated care services.
There are many high-quality health technology and biotechnology companies in the Science Park ecosystem. At present, there are more than 210 park companies and incubators engaged in biomedical technology in the park, which are growing rapidly and have considerable strength in translational research.
"The Science Park will open up more co-creation opportunities to promote the integration and wide application of research results with clinical services," said Mr Wong.
(Contract)

International collaborations can facilitate innovative clinical products and patient-centered care.

Establishing a drug shortage center and reviewing health insurance drug pricing can help address shortages.

International collaborations are crucial in addressing global medication shortages.

The global healthcare sector faces a severe workforce shortage, with a projected deficit of 10 million staff by 2030.

Title:

Content: The revolution of artificial intelligence in the field of medical diagnosis _ Su Zhongcheng
Written by MetaHero
Published: Updated:
Artificial intelligence (AI) is expected to reshape medical diagnostics by 2024, bringing unprecedented precision and efficiency to improve patient care. AI-driven diagnostic tools leverage machine learning algorithms to improve the accuracy of early disease identification, which is critical for effective treatment and improving patient outcomes.
This not only optimizes outcomes, but also represents a paradigm shift in healthcare towards more personalized care.
By Michael C.S. So (Visiting Assistant Professor, Graduate School, Lingnan University)
The integration of AI in healthcare systems is also expected to streamline workflows, thereby reducing the burden on healthcare professionals and potentially reducing burnout.
By automating repetitive tasks, such as data entry for electronic health records and processing insurance authorization requests, AI enables clinicians to focus more on patient care than on administrative duties.
In addition, the role of AI in supporting staffing needs cannot be underestimated. With the global healthcare sector facing a potential shortage of 10 million doctors, nurses, and midwives by 2030, AI tools provide practical solutions to these challenges.
They help identify diseases earlier, prioritize emergency cases, and support healthcare workers in their daily tasks.
With the healthcare AI market projected to grow to nearly $188 billion by 2030, the industry is at a critical crossroads. The adoption of AI in healthcare promises to enhance care, advance health equity, and transform patient outcomes.
However, it is critical to embrace this technological advance responsibly, with a focus on ethical considerations and the fair distribution of its benefits.
All in all, AI will transform medical diagnostics by improving the accuracy and efficiency of disease detection, personalizing patient treatment plans, and supporting the work of healthcare professionals. The potential benefits are huge, but must be balanced with approaches to carefully manage the associated risks to ensure that AI is patient-centered and inclusive in healthcare.
Application Example
Cardiac diagnostics: Innovations such as Tricog ’ s InstaECG and InstaECHO demonstrate the significant impact of AI in heart care.
These technologies enable accurate and timely diagnosis of life-threatening cardiovascular conditions, enhance remote diagnostic capabilities and empower healthcare providers with better patient outcomes. (InnoHEALTH Magazine)
Eye enhancement: In eye care, AI is used to detect conditions such as diabetic retinopathy.
Alavinde Eye Hospital has partnered with Google to use machine learning to improve the accuracy and accessibility of ophthalmic diagnostics, demonstrating the potential of AI in professional medical applications. (InnoHEALTH Magazine)
Stroke care and imaging: Viz.ai uses AI to improve stroke care, improving services with advanced image analysis and real-time data processing.
Their technology facilitates faster, more informed decision-making, highlighting the critical role of AI in acute care. (Techopedia)
Automated clinical documentation: DeepScribe ’ s AI technology automates the creation of clinical documents, reducing the administrative burden on healthcare providers.
This integration not only improves efficiency, but also allows doctors to focus more on patient care than on paperwork. (Techopedia)
Conversational diagnostics: The AMIE system optimizes AI for diagnostic conversations, combining medical reasoning with effective communication skills.
This technology improves diagnostic accuracy while maintaining empathy and clarity in patient interactions, demonstrating AI ’ s ability to improve the quality of patient care.
(Google Research)
Infectious disease detection: The application of AI in detecting ultrasound images of the COVID-19 lungs demonstrates its utility in infectious disease management.
This capability is critical for the early detection and management of disease, demonstrating how AI can support public health initiatives by improving diagnostic accuracy in critical care settings. (Med Xpress)
These examples clearly demonstrate the broad application and far-reaching impact of AI in medical diagnostics, not only as technologically advanced, but also in terms of ethics and quality, ensuring integrity and trust in medical practice.
As we move into a data-driven medical future, AI continues to expand its scope of application by providing more accurate disease detection, personalized treatment plans, and enhanced medical professional support. Innovation and ethical considerations will be key to driving progress in this area.
These outlook and case studies provide us with a more comprehensive understanding of how AI can act as a powerful driver of change in medical diagnostics, and highlight ethical and quality control issues that must be considered when embracing these technologies.
As technology evolves, the role of AI in healthcare systems around the world will become more and more important, with far-reaching implications for both healthcare professionals and patients.

AI and ML are being applied to address medication shortages by creating operational efficiencies in pharmaceutical companies.

Title:

Content: BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

What Got The Pharma Industry Here Won’t Get It There: Navigating A Complex Path Forward

Click to save this article.
You'll be asked to sign into your Forbes account.
Got it

Arda Ural, PhD | EY Americas Industry Markets Leader, Health Sciences and Wellness.

The economic outlook for 2024 seems to be stuck between a persistent labor market, stronger-than-expected consumer spending and stubborn inflation that is not dropping fast enough for the Federal Reserve to feel comfortable to start tapering its short-term borrowing rates. Beyond these conflicting macroeconomic dynamics, there is geopolitical unrest around the globe, and 2024 will observe multiple key elections in the world. This convergence of circumstances makes for an uncertain business environment that impedes capital spending.

Against that backdrop, pharmaceutical companies also must deal with unique industry-specific challenges. The industry is treated as a countercyclical one by investors and has historically shown resilience during economic downturns.

As the industry has increased its output over the last 30 years, the number of dispensed prescriptions has consistently increased, according to IQVIA data analyzed by EY, suggesting an inelastic demand for essential medicines regardless of the broader economy. This remained true during the dot-com bust of the early 2000s and the subprime mortgage crisis from 2007 to 2009. Prescriptions saw a slight dip at the start of the pandemic due to initial lockdowns but then recovered.

However, what got the industry here may not get it there. The challenges are aplenty and start with an expected $300 billion erosion of the topline over the next five years due to the expiration of patents on many of the best-selling biologics of the last decade, as per Evaluate Pharma.

The other issue for the industry is the squeeze of its cost structure. The industry’s SG&A spending as a percentage of its revenue is stuck at 28% over the last decade while its R&D spend on clinical trials has gradually edged up from 11.8% (or $32 billion) in 2000 to 18.4% (or $162 billion) in 2023, according to data compiled by EY using CapIQ. The number of globally run clinical trials registered with ClinicalTrials.gov since its creation in 2000 has increased from 2k to nearly 500k. The innovation business is intrinsically risky where only ~5% of product candidates entering the clinical studies end up approved for human use.

Costs are expected to continue to rise for the industry. EY analysis shows a 30% to 65% increase in energy prices, a 50% to 160% increase in the input costs for raw materials and a 6% to 10% increase in the cost of labor should be expected.

Finally, our research showed that about 70% of product launches did not meet or exceed analyst expectations, indicating that the commercial success hurdle has been increasing primarily due to market access and drug reimbursement challenges.

While the industry sits on more than $1 trillion in its balance sheet, according to the EY Firepower report, filling pipelines to make up for the losses to exclusivity for key products has proved challenging. Due in part to the macroeconomic landscape but also the complex regulatory landscape, the deal-making environment has been muted over the last two years.

All these dynamics are forcing pharmaceutical companies to cut costs to bolster the bottom line to be able to fuel its innovation engine.

Emerging technologies like artificial intelligence (AI) and machine learning (ML) can help pharma companies create operational, financial and workforce efficiencies. Already, many companies are experimenting with using AI to automate back-office operations, streamline paperwork and enable employees to better focus on critical tasks and priorities.

The technology is also being applied across the life cycle of product development, specifically in areas like drug discovery, R&D and commercialization, while areas like manufacturing, supply chain and distribution and quality control are still in the early phases of adoption. Companies are using these emerging technologies for drug discovery, lead candidate selection, protocol development, clinical operations such as site selection, patient recruitment, trial management and stakeholder engagement.

While emerging technologies like AI are unlikely to change the fundamental business model of pharmaceutical companies in the near term, they will have a broad and significant impact on development timelines, as well as the costs associated with bringing novel medications to patients to meet unmet medical needs.

AI/ML is probably more hope than hype—unlike some earlier technologies such as blockchain and metaverse, which came with massive expectations. My opinion is that the capabilities AI/ML will make available for the industry are necessary but not sufficient. So, the industry needs to reimagine itself along the people, process and technology fronts to innovate through this business cycle as it has during prior challenges.

Forbes Finance Council is an invitation-only organization for executives in successful accounting, financial planning and wealth management firms. Do I qualify?

Follow me on Twitter or LinkedInCheck out my website

AI is being used in drug discovery to optimize development timelines and costs.

Aide Chemists uses AI to predict medication demand in Africa and improve health outcomes.

Title:

Content: Aide Chemist, Casual Foundry join hands to improve health delivery

0

Causal Foundry and Aide Chemists have forged a collaborative partnership to introduce AI-powered personalization and prediction of demand technologies to communities in Africa to improve health outcomes.

Through this partnership, the integration of artificial intelligence (AI) will be enhanced in the day-to-day operations of Aide Chemists and the personalization of healthcare for patients.

This integration, according to a statement from the two parties, will involve incorporating Aide Chemists’ ERP, developing Momentum E-Commerce and Patient Health Management Platform and connecting distribution and e-commerce systems to Causal Foundry’s AI Reinforcement Learning platforms.

By doing so, comprehensive insights into the operations of Aide Chemists will be provided, particularly in low to middle-income communities where Aide Chemists branches and Momentum franchise networks are located in Ghana.

The primary focus of this partnership is to conduct adaptive experiments that deepen the
understanding of disease prevalence patterns through drug management interventions, analyse patient demand, and monitor health outcomes through impactful interventions, especially in relation to the Aide Cares Programme.

The Aide Cares Programme is the flagship initiative of the pharmacy chain, aimed at making medicines affordable and accessible to vulnerable communities, particularly those affected by chronic conditions such as diabetes and hypertension.

Chief Product Officer, Pharmacist, and Co-Founder of Aide Chemists, David Addo expressed his enthusiasm for the agreement, stating, “Our primary goal is to provide high-quality
healthcare to our patients. Employing innovative solutions is crucial in improving patient health outcomes and achieving key Sustainable Development Goals (SDGs) for our company and the nation as a whole.

“We firmly believe that an increasing number of Ghanaians will come to recognize the potential of AI in meeting their healthcare needs. We take great pride in being the
first pharmaceutical company in Ghana to offer these solutions through our collaborative
partnership with Causal Foundry.”

David Addo said the timing of this integration aligns perfectly with the launch of Momentum, Aide Chemist’s app designed to engage with patients, which complements its  . existing online pharmacy platform, adding that “undoubtedly, this integration will have a significant impact in this regard in offering personalized care for the vulnerable.”

CEO and Co-Founder of Aide Chemists, Abigail Abora expressed her satisfaction with the collaboration, emphasizing that “the profound insights gained from this partnership will enhance the efficiency of our operations and enable us to monitor our interventions in healthcare delivery with clarity and purpose. I am delighted that our collaboration will allow Ghanaians to witness the direct benefits of AI in healthcare.”

On his part, the CEO and Co-Founder of Causal Foundry, Dr. África Periáñez expressed her delight at the collaboration, stating, “Pharmacies are a critical access point and integral to frontline healthcare. We are thrilled to partner with Aide Chemists to support pharmacists’ work by optimizing supply chain information, personalizing recommendations to the needs of their communities, and supporting patients in their decision-making processes and adherence to treatments.”

She added, “We are excited to work with Aide Chemist to bring the latest reinforcement learning and generative AI technologies and put the pharmacy technology landscape of Ghana at the forefront of AI, with only one goal of improving healthcare outcomes for patients.”

Overall, this collaboration marks a significant milestone for both Aide Chemists and Causal
Foundry as they jointly endeavor to leverage AI technologies to transform healthcare delivery, improve patient outcomes, and contribute to the advancement of healthcare in Africa.

Send your news stories to newsghana101@gmail.com Follow News Ghana on Google News

The company has partnered with Causal Foundry to optimize its supply chain and make medicines more affordable using AI.

AI can deepen biology understanding and speed up new drug discovery, helping address medication shortages.

Title:

Content: Healthcare companies moved higher as tech companies continue to enter the space.

Facebook parent Meta Platforms has created a tool to predict the structure of hundreds of millions of proteins using artificial intelligence. Researchers say it promises to deepen scientists' understanding of biology, and perhaps speed the discovery of new drugs.

Meanwhile, a drug used to extend the lives of people with advanced prostate cancer is in short supply and will be for months, leaving some patients with no treatment option as the manufacturer works to ramp up production. The Food and Drug Administration said last week the availability of Pluvicto is limited as manufacturer Novartis struggles to meet demand. The drugmaker said the shortage stems from manufacturing and delivery issues.

Write to Amy Pessetto at amy.pessetto@dowjones.com

(END) Dow Jones Newswires

03-16-23 1727ET

AI in precision medicine improves care quality and safety through personalized analysis of patient data.

Title:

Content: Cesil completes strategic plan for personalized medicine

Without haste, but without stopping, Piano, Piano, Castilla y León lays out its strategic plan for personalized therapy with well-woven wicker. It can claim to be one of the autonomous communities with the highest speed of implementation, a revolution with many challenges and a paradigm shift between classical medicine – focused on the disease – and precision medicine, which allows designing ‘tailor-made’ Tries to refine till. Suit’.’ To treat each patient. And it does this from massive amounts of data, data that heals, and where artificial intelligence also makes room to be able to process and interpret such a mix of information that, because of its complexity and volume, no longer Cannot be managed in the traditional way. ,

A study by the Roche Institute, one of the most rigorous in Spain, highlighted five years ago that Castilla y León was in third place among the group of autonomies with the greatest development in personalized and precision medicine. Its methodology was defined as a state reference model with the potential for implementation in other regions, which is constantly growing. Now, the Ministry of Health is completing its roadmap that will serve to integrate, provide a framework and enhance the many initiatives developed over the last decade and which have consolidated it as a reference for many centers and pathologies.

It is not in vain that personalized and precision medicine has been considered a positioning element for large international economies, in which Spain, after taking up the challenge thrown in 2015 by the then President of the United States Barack Obama, began to act in 2019. . Five years ago, he created the Senate’s study report on genomics, which ended with 13 recommendations, where Castilla y León had already started “with a privileged position”.

Maria Isidoro, head of the Clinical and Biochemistry Analysis Service of the Salamanca Healthcare Complex and regional coordinator of the Strategic Plan for Personalized Precision Medicine, explains this to Ikal, whose experience has also helped her to be included in the list of consultants. The Ministry of Health, which works in a transversal portfolio to ensure the inclusion of genomic, personalized and precision medicine in the portfolio of general services of the National Health System in primary and hospital care, as indicated by the findings of the presentation.

“In Castilla y León we start from a privileged position with many previous initiatives. The strategic plan will be the framework to gather all these initiatives and promote them, so it is quite advanced,” says Isidoro, noting that To emphasize that Precision already represents “a revolution in care” with “significant improvements in the quality of care, increased safety, greater accuracy in diagnosis and greater likelihood that treatments will be more effective”. This also includes cost reduction “and not at the expense of the patient’s health, but in favor of their safety.”

rare diseases

Initiatives that are already bearing fruit in Castilla y León, and prioritized by the Strategy on Genomic, Personalized and Precision Medicine for the National Health System, are the approach and genomic sequencing of patients with rare diseases. A year ago, the Community launched the PiERCyL Comprehensive Plan, which has recently been recognized with the MERCOS-ODS National Distinguished Leadership Award, and which has established a model support structure that is helping the design of the regional global plan. This was a big step, since then patients in Castilla y León have been “pioneers” in large-scale whole genome sequencing in a healthcare way, within a portfolio of services, supported by artificial intelligence for the analysis of information.

“The impact of personalized medicine on rare diseases is huge.” “In Castilla y León, a coordinated health care system has been established, from primary to hospital care; between laboratory and clinic, and between different health sectors in the field of pediatrics” which allowed to analyze more than 5,000 patients Thanks to “the Advanced Diagnostic Unit for Rare Diseases of Castilla y León, located in the Hospital of Salamanca, a network structure that now develops the adult sector with the coordination of care nodes and multidisciplinary reference teams.”

pressure characteristics

But the roadmap of Castilla y León goes further, incorporating a comprehensive package of specialties that includes pharmacogenetics, making room for precision psychiatry, cardiology, pathology and precision allergology that have been providing their services for years. Fruit.

In the case of precision cardiology, the Cardiology Service of Salamanca has a Family Cardiology Unit, designated as a CSUR Center – which answers to the centres, services and referrals of the National Health System – and which is now congenitally Desires to achieve this recognition. heart disease.

The community is also a leader in precision pathology, which is one of the pillars of precision oncology, as well as precision medicine, which uses predictive information for precise oncological treatment. Precision pathology also extends to other non-oncological diseases, although it is in this last area where the most progress has been made with drugs specific for specific molecular and genetic alterations. This has been contributed by the Network for the Study of These Diseases, which is supported by a biobank based in the Cancer Research Center, Salamanca, and which coordinates the biobanks of seven hospitals.

“We perform molecular studies on samples from cancer patients. Depending on the type of cancer, we analyze a series of genes whose alteration leads to a specific treatment. We are talking about biomarkers and the development of targeted drugs. With oncological treatment is precise,” the chief summarized. Of cancer service. Maria Dolores Ludeña, Director of Pathological Anatomy of the Salamanca University Care Complex, who recognizes the importance of the arrival in the community a year ago of the first massive next generation sequencers, which allows “with very little DNA”. “The RNA sample studies a large number of genes and the diagnosis is made relatively quickly, within a few days”. This year, they have already studied about 400 patients.

“This gives us very good information about the molecular changes of the tumor that can be treated in a precise, personalized way,” says Ludena, who specifies that Salamanca is a reference center for Zamora and Ávila. In addition, similar molecular studies are being carried out in León and Burgos, and they are being completed in Valladolid. In fact, this year, SACIL will provide large-scale sequencers to the hospitals of León and the Valladolid Clinic to advance in this field. “Four reference centers have been proposed for the entire community,” so that “no one is left out.”

pharmacogenetics

Another thread woven by the regional strategy is its own model, recognized internationally, for rationalizing medical prescriptions ‘Five Step Precision Medicine 5SPM’, promoted by Dr. María Isidoro García, which is now being implemented in a new The system will be strengthened. To systematically apply artificial intelligence, personalized precision medicine, to pharmaceutical prescriptions in chronic patients. To date, this has allowed us to refine the treatment of more than 2,500 patients from multiple services, says Isidoro.

The new artificial intelligence project has funding of approximately 700,000 euros, part of this year’s 2.3 million euro 5P plan of the National Health System for Communities. The tool will work online and in real time, initially in the field of specialized care and later in primary care. The aim is not only to increase the safety of polymedicated patients by reducing the risk of adverse effects; But by focusing prescriptions on the most indicated drug, medicinal effectiveness is also increased by removing those drugs that, due to metabolic interactions, limit the mechanisms of action of the remaining drugs, which implies reduced drug costs associated with unnecessary prescriptions. To reduce and reduce. Health costs associated with the consequences of adverse effects.

The 5SPM model has demonstrated over its 15-year history that, compared to the classic approach, the adaptation of medical treatment to the individual characteristics of the patient results in significant improvements in health and quality of life, as well as saving resources for the system . , “Pharmacogenetics studies the gene variations that determine response to drugs and is a fundamental pillar in personalized precision medicine. Prediction of the response to a certain treatment allows applying preventive or therapeutic interventions and guiding the prescription in a different The benefit represents a more appropriate treatment”, says Isidoro.

artificial intelligence

Artificial intelligence tools play an essential role in the field of precision medicine to help process and interpret such amounts of data. Many hospital services in Castilla y León are beginning to resort to these devices, some pioneering, as is the case of the Allergy Service of the Salamanca University Care Complex, in collaboration with the GIR (Recognized Research Group) Robotics and Society of the University. Salamanca has developed an artificial neural network (ANN) to predict patients who are allergic to beta-lactams, a group of antibiotics where penicillins are most commonly included, so that those at lower risk can be identified. So that beta-lactams can be used safely. In urgent situations, without the need for exhaustive study, explains Esther Moreno Rodilla Ikal.

Currently, and in collaboration with experts from the University of Salamanca, they are developing another project based on Natural Language Processing (NLP) and deep learning techniques. “The main objective of the project is to investigate the usefulness of these techniques in predicting the risk of allergy to beta-lactams. To date, more than 4,000 medical records of the patients studied have been analyzed in our service. Processing and intelligence After obtaining the model, the use of artificial, ‘machine learning’ tools is proposed, which, together with the above model and the decisions taken by allergy doctors, allows us to develop an AI application that can make the predictions necessary for correct risk labeling Is. patients.”

Once the model is obtained, the next approach would be to analyze its usefulness in a multicenter study involving other allergy services from different areas of the national region. “The ultimate aim of the model will be to be able to accurately risk stratify patients with suspected allergy, but without confirming allergy studies, and who require immediate treatment with beta-lactam antibiotics.”

With these well-woven wicker, Castilla y León now carries out its personalized precision medicine planning. Additionally, along with others from various hospitals in the community, where initiatives for early detection of dyslipidemia are being launched; Application of artificial intelligence to new pathological anatomy rings; AI in the field of neurosurgery, as the Rio Hortega University Hospital in Valladolid is doing, or in Burgos to prevent falls in Parkinson’s patients. There are many more teams and projects in the community who are innovators and pioneers who will contribute to advancing this ‘tailored suit’ for the patient, thanks to the past decade of refining disease prevention, diagnosis and treatment. It is a big step. Efforts and actions that outline the medicine of the future already exist.

(TagstoTranslate)Medicine(T)Leon(T)Castilla y León(T)Artificial Intelligence(T)Salamanca(T)Rare Diseases(T)Diseases(T)Health(T)Primary Care(T)Pharmacy(T)SACIL( t)Health

Source link

About Admin

Check Also

Religious freedom and animal welfare

It is one thing that animals do not participate in our situation as humans, and ... Read more

AI tools predict patient allergy risks to certain antibiotics, reducing costs and adverse effects.

The global AI medical market is expected to grow from $4.9 billion in 2020 to $45.2 billion by 2026.

Title:

Content: Medical AI is not to help patients see a doctor, but to assist doctors to implement a more complete medical process; even through continuous learning and evolution, to meet the medical system and regulations of different countries, to form a customized medical AI.
In recent years, the most popular topic of concern is the emergence of digital medical trend built by Bio + ICT, and the more sophisticated medical neural network, artificial intelligence (AI), has entered the early stage, but there are still many unmet medical needs, and more than five years since its establishment, there have been several products on the market. Changjia Intelligence has been at the forefront of medical AI, and has built medical AI that is more close to clinical needs and more in line with different national medical systems and processes, breaking through the existing framework, and making response and contingency plans for future regulatory adjustments and progress.
Medical AI “Values ” to be discovered
The global AI medical market has reached US $4.9 billion in 2020, and Markets and Markets expects to grow to US $45.2 billion by 2026, with an annual compound growth rate of 45%. The growth momentum comes from several aspects, one is the continuous increase in data volume and complexity of data sets (including new diagnostic devices and sensors, driving the demand for AI); the other is The third is the shortage of medical resources caused by an aging population; and finally, the introduction of AI into new drug research and development by pharmaceutical and biotechnology companies.
As mentioned earlier, because AI can rapidly analyze huge amounts of biological science information, including genes, molecular / protein structures, patents, biologic journals, and databases, etc., greatly accelerating the discovery of candidate drugs, drug development is currently the most important application, accounting for up to 28%; and medical image recognition and diagnosis, accounting for 24%. This is because image interpretation is the most mature application of AI, and the accuracy is not far from that of human doctors.
At present, although a considerable number of medical AI products have entered the international market, most people still have the myth of medical AI, thinking that "medical AI is to help patients diagnose and treat". In fact, the biggest function of medical AI is to assist doctors to interpret and formulate treatment strategies, not to replace the natural duty of doctors. After the operation, the result was that the vital signs were unstable, and the process was quite complicated. Although the final operation was successful, it was still proposed by the hospital to conduct a medical review. The result was that when the emergency patient came in, there was an X-ray, and there was a small pneumothorax in the X-ray, which was very dangerous for anesthesia and intubation.
Of course, there are many structural factors, and doctors are not gods and need to rest, but with a sleepless AI, all possible risk assessments will be revealed, so that errors in the medical process can be avoided.
Medical AI R & D tends to be customized
For example, the radiation oncology department, when carrying out the treatment plan, must outline the tumor around the organ, this is a meticulous work, if there is AI can help to do a lot of similar things, not only outline the precision but also very complete, the doctor can have more time to think and help the patient formulate the medical process.
A lot of medical AI is a problem faced by doctors in clinical diagnosis, which has developed in line with the value of medical AI.
In other words, medical AI is like a doctor ’ s assistant, not only fast, accurate, and even able to achieve the effect of warning in advance, taking a long time to look at the overall medical process cost is still cheap.
For the full text and chart, please refer to "Investment Weekly 2231-2232 Joint Issue".
# Changjia Intelligence # Medical # Doctor # Patient # Several

The AI market growth is driven by the shortage of medical resources due to an aging population.

Omnicell provides medication automation solutions to over 50,000 North American pharmacies.

Title:

Content: Skip to content

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology …

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology …

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication … It is estimated that drug shortages are costing facilities at least $359 million per year in … More than 50,000 institutional and retail pharmacies across North America …
See all stories on this topic

Nearly 75 per cent of Ontario doctors experienced burnout during pandemic, survey says …

Nearly 75 per cent of Ontario doctors experienced burnout during pandemic, survey says … as COVID-19 was first hitting North America – that saw 66 per cent of respondents report some level of … Dr. Adam Kassam, president of the OMA, said physician burnout has always been a problem, but it’s been …
See all stories on this topic

Health researchers report funder pressure to suppress results – Nature

These trials, published between 2007 and 2017, were cited in Cochrane reviews, which are considered the ‘gold-standard’ of evidence used to inform …
See all stories on this topic

Survey: nearly 75 per cent of Ontario doctors experienced burnout during pandemic – Toronto Star

Dr. Carolyn Snider felt a gamut of emotions while working in one of the busiest emergency rooms in Canada during the last 18 months of the …
See all stories on this topic

Asia-Pacific Over the Counter (OTC) Drugs Market 2021 Segmented by Product, Distribution …

North America currently holds the largest share in the market, due to the increasing expenditure in healthcare. Inclination of Pharmaceutical Companies …
See all stories on this topic

Published inSubstance Abuse

Drug shortages cost facilities at least $359 million annually, affecting 99% of hospitals.

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

The FDA is allowing imports and hospitals are rationing or offering alternatives to address chemotherapy drug shortages.

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

AI and big data are improving drug R&D design and efficiency, including predicting protein structure.

Title:

Content: People 's Daily Online > > Economy and Technology
China 's new drug research and development force to promote the second echelon, "14th Five-Year" how to rise to the next level?
Zhang Jiaxing
March 02, 2022 09: 21 | Source: Science and Technology Daily
Small number
“According to the latest data released by McKinsey in 2020, China ’ s new drug research and development accounts for 13.9% of the world ’ s total, ranking second. ”
At the China Pharmaceutical Industry Development Conference on February 26-27, Chen Kai, vice president of major special technology for the creation of new drugs and academician of the Chinese Academy of Sciences, showed his achievements and also posed challenges.
At present, China's annual production of medicines is hundreds of thousands of tons, but most of the value is low, and there is a clear gap with the United States, which is the first tier of drugs.
"It is very important to find the source of new drugs to solve clinical problems," said Wang Chen, vice president of the Chinese Academy of Engineering, president of the Chinese Academy of Medical Sciences and president of the Peking Union Medical College.
The international R & D path of new drugs is generally in clinical demand, the laboratory (through mechanism research) to find targets, the company follow-up (transformation) research.
However, there are still some problems in the research and development of new drugs in China at the source, such as finding targets from foreign literature and secondary innovation based on foreign original research drugs.
"In order to comply with the 14th Five-Year Plan, pharmaceutical innovation should adhere to demand-oriented and problem-oriented, break the rigid disciplinary boundaries, and actively promote interdisciplinary integration."
Wang Rui, an academician of the Chinese Academy of Engineering, executive director of the Institute of Medicine of the Chinese Academy of Medical Sciences, and vice president of Lanzhou University, said at the meeting that the current medical field should overcome the disadvantages of single-handedness and scattered resources, focus on major practical problems, serve major national needs, and further promote organized scientific research.
Research and development innovation in the field of medicine directly faces people's lives and health.
China 's new drug research and development force has been ranked in the second echelon, "14th Five-Year Plan" how to go to a higher level? How can China' s pharmaceutical innovation shoulder the task of promoting industrial development and meeting clinical needs?
Dozens of academicians spoke together at the China Pharmacy Development Conference hosted by the Chinese Academy of Medical Sciences.
Clinical resources need to be used more fully
In the new drug research and development chain in China, clinicians are used to joining from the first clinical stage or later than the first clinical stage, which makes it difficult to fully meet the clinical needs of new drug research and development from the source, and also makes the original innovation of new drug research and development in China insufficient.
"China is rich in clinical research resources, but it will encounter many problems clinically."
Wang Chen exemplified that a small molecular diagnostic reagent needed by the respiratory department has not been developed in China, and the clinical use of industrial preparations has been replaced until recently, when clinicians and pharmaceutical experts cooperated in research and development, this problem was solved.
The following set of data gives a more intuitive sense of the gap.
"The number of hospitalizations in China is about 200 million every year, and the average hospitalization day is 8-10 days, totaling 1.6 billion to 2 billion bed days, which are relatively fine materials to study," Wang Chen said.
However, in the face of such huge clinical research data, no effective data research conclusions have been formed.
In the global registered clinical research, the number of registered studies in China accounts for only about 3%.
Relevant experts said that for the 14th Five-Year Plan, efforts should be made to improve the system of production, education and research, improve the level of open cooperation in pharmaceutical science and technology innovation, fully stimulate the willingness of clinicians to explore clinical needs, and more deeply integrate into the complete ecological chain of pharmaceutical research and development.
With big data, artificial intelligence is the direction of development
"With the continuous development of new drug research experimental technology, such as multi-omics technology, high-throughput screening technology, DNA coding technology, structural biology technology, etc., have generated massive data, and effective analysis and mining of these data will effectively promote the research of innovative drugs in China." Chen Kaixian said.
According to the data, many multinational pharmaceutical companies such as Merck and Johnson & Johnson have cooperated with AI companies in the development of new drugs.
Some people believe that in the next 3-5 years, candidate drugs that have not been studied by AI-driven models will not be able to enter clinical trials.
"Through the amino acid sequence of the protein, it can predict its three-dimensional structure, which plays a very important role in drug research." Chen Kaixian introduced, China's artificial intelligence-enabled drug research and development work is also continuing to advance.
According to reports, Huawei and the Shanghai Institute of Medicine of the Chinese Academy of Sciences jointly developed the iPhord algorithm, and the prediction accuracy of the protein folding structure on the international authoritative test platform exceeded the existing best algorithm by 20%, achieving the "target ten rings".
"In the future, our team will seek new breakthroughs and new progress in drug induced protein structure change, protein and protein interaction structure change." Chen Kaixian said that precision drug design based on big data and artificial intelligence technology will make new drug R & D design more advantageous, shorten drug R & D time, improve R & D efficiency, and control R & D costs.
(Editor: Wang Zhen, Chen Jian)
Share it so more people can see it.
Back to top

India's AI in drug discovery market is expected to reach INR 2.57 trillion by 2028.

Title:

Content: India Artificial Intelligence in Drug Discovery Market Report 2023-2028: Leveraging AI for Success - Next-Generation Drug Discovery, Efficiency and Accuracy, Addressing the Healthcare Burden

Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Drug Discovery Market in India, 2024" report has been added to ResearchAndMarkets.com's offering.

The Indian market for artificial intelligence (AI) in drug discovery is projected to grow to INR 2.57 trillion by 2028, with a compound annual growth rate (CAGR) of 30.82% from 2023 to 2028.

AI is poised to become a lucrative technology in healthcare, filling the research and development gap in drug manufacturing and enhancing targeted drug production. As a result, biopharmaceutical companies are increasingly embracing AI to bolster their market presence.

In India's drug discovery field, AI utilizes advanced computational techniques to expedite various stages of drug development. AI is pivotal in deciphering intricate biological data, simplifying target identification, and enhancing lead compound searches. The incorporation of machine learning, deep learning, and natural language processing enables the analysis of vast datasets, facilitating predictive modelling for personalized medicine, drug interactions, and biomarker discovery.

Market drivers:

The rising prevalence of chronic diseases, such as heart disease, diabetes, cancer, and neurological disorders, underscores the growing healthcare burden, necessitating prolonged treatment.

Drug discovery plays a pivotal role in identifying effective therapies for these conditions, with AI, particularly leveraging machine learning and deep learning applications, meeting this demand by efficiently analyzing extensive datasets encompassing genomics, proteomics, and clinical data. As technologies evolve, especially in machine learning, deep learning, and data analytics, AI becomes increasingly transformative in pharmaceutical research and development, enabling the analysis of intricate biological datasets with unprecedented efficiency and accuracy.

Market challenges:

The stringent regulations and guidelines present a challenge, hindering the seamless integration of AI into India's drug discovery market. While vital for patient safety and data integrity, the complexity of regulatory frameworks may not always align smoothly with the rapidly evolving landscape of AI technologies.

Additionally, the efficacy of AI relies on substantial data volumes, crucial for system training, but acquiring diverse data from various providers can entail additional expenses for companies.

Key Topics Covered:

Chapter 1: Executive summary

Chapter 2: Socio-economic indicators

Chapter 3: Introduction
3.1. Market definition and structure
3.2. Major applications of AI in drug discovery
3.3. Use cases of AI in drug discovery

Chapter 4: Market Overview
4.1. Artificial intelligence in drug discovery market - an overview
4.2. Market size and growth forecast based on value (2020-2028e)

Chapter 5: Market Trends
5.1. Key market trends

Chapter 6: Impact of COVID-19
6.1. Impact of COVID-19

Chapter 7: Market Influencers
7.1. Market drivers
7.2. Market challenges

Chapter 8: Competitive Landscape
8.1. Tata Consultancy Services Limited

  • Company information
  • Business description
  • Products/services
  • Key people
  • Financial snapshot
  • Key ratios
  • Key financial performance indicators
  • Key business segments
  • Key geographic segments

8.2. Wipro Limited
8.3. Google India Private Limited
8.4. IBM India Private Limited
8.5. Microsoft Corporation India Private Limited

Chapter 9: Major Start-ups

Chapter 10: Recent Developments

For more information about this report visit https://www.researchandmarkets.com/r/izrlu1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Data

Stringent regulations are hindering AI integration in India's market, but AI technologies are transforming pharmaceutical research and development.

AI and ML are being applied to address medication shortages by improving operational efficiencies and optimizing development.

The effectiveness of solutions to address medication shortages is being evaluated using metrics such as the number of drugs in shortage, duration, and impact on patient care.

Quality metrics, including defect rates, customer satisfaction, and on-time delivery, assess the performance of solutions to address medication shortages.

Title:

Content: How to monitor quality?

Monitoring quality is a crucial aspect of any business operation, as it ensures that products or services meet established standards and customer expectations. The process of monitoring quality involves systematically checking and evaluating the various aspects of a product or service to identify and correct any deviations from the desired quality level. By monitoring quality effectively, businesses can ensure customer satisfaction, improve efficiency, and maintain a competitive edge in the market. In this article, we will discuss the importance of monitoring quality and provide some tips on how to do it effectively.

The Importance of Monitoring Quality

Monitoring quality is essential for businesses to ensure that their products or services consistently meet customer expectations. By monitoring quality, businesses can identify any issues or defects in their products or services early on and take corrective action before they escalate. This helps to reduce the likelihood of customer complaints, returns, or recalls, which can damage a company’s reputation and bottom line. Additionally, monitoring quality allows businesses to identify areas for improvement and make necessary changes to enhance product or service quality over time.

How to Monitor Quality

**1. Establish clear quality standards:** Before you can monitor quality, you need to establish clear quality standards that define what constitutes a high-quality product or service. These standards should be based on customer expectations, industry best practices, and any relevant regulations or quality certifications.

**2. Define measurable quality metrics:** Once you have established quality standards, you need to define measurable quality metrics that can be used to assess the performance of your products or services against these standards. These metrics could include defect rates, customer satisfaction scores, on-time delivery rates, or any other relevant indicators of quality.

**3. Implement quality control processes:** Implementing quality control processes is essential for monitoring quality effectively. These processes should include regular inspections, testing, and audits to identify any deviations from the established quality standards. It is also important to involve employees at all levels of the organization in quality control efforts to ensure that everyone is committed to maintaining high-quality standards.

**4. Use quality management tools:** Quality management tools can help streamline the monitoring process by providing real-time data on quality metrics, tracking quality issues, and generating reports for analysis. These tools can range from simple spreadsheets to more advanced quality management software that includes features like automated alerts and corrective action tracking.

**5. Conduct regular quality reviews:** Regular quality reviews are essential for monitoring quality over time and ensuring that any quality issues are addressed promptly. These reviews should involve key stakeholders from different departments and include a thorough analysis of quality metrics, trends, and any corrective actions taken.

**6. Seek customer feedback:** Customer feedback is a valuable source of information for monitoring quality and identifying areas for improvement. Encourage customers to provide feedback through surveys, reviews, or direct communication channels, and use this feedback to make informed decisions about how to enhance product or service quality.

**7. Train employees on quality standards:** Training employees on quality standards is essential for ensuring that everyone in the organization understands their role in maintaining product or service quality. Provide regular training sessions on quality standards, quality control processes, and the importance of quality in meeting customer expectations.

**8. Establish a culture of continuous improvement:** Quality monitoring should not be a one-time effort but rather an ongoing process of continuous improvement. Encourage a culture of continuous improvement within the organization by soliciting feedback from employees, implementing suggestions for quality improvement, and celebrating successes in maintaining or improving quality standards.

**9. Monitor suppliers and vendors:** If your business relies on suppliers or vendors for materials or components, it is essential to monitor their quality to ensure that it meets your standards. Establish quality requirements for suppliers, conduct regular audits, and address any quality issues promptly to prevent them from affecting your products or services.

**10. Implement a corrective action process:** When quality issues are identified, it is important to have a robust corrective action process in place to address them effectively. This process should include investigating the root cause of the issue, implementing corrective actions, and monitoring the effectiveness of these actions to prevent similar issues from reoccurring.

**11. Benchmark against industry peers:** Benchmarking your quality performance against industry peers can provide valuable insights into how your products or services stack up against the competition. Use benchmarking data to identify areas of strength and weakness in your quality management processes and make strategic decisions to improve overall quality performance.

**12. Stay informed about industry trends:** Staying informed about industry trends and best practices in quality management is essential for keeping your quality monitoring efforts up-to-date. Attend industry conferences, participate in professional organizations, and engage with quality management experts to stay informed about the latest trends and technologies in quality monitoring.

In conclusion, monitoring quality is a vital aspect of running a successful business. By establishing clear quality standards, defining measurable quality metrics, implementing quality control processes, and following the tips outlined in this article, businesses can effectively monitor quality and ensure that their products or services meet customer expectations consistently. Remember that quality monitoring is an ongoing process that requires commitment, collaboration, and a focus on continuous improvement to achieve long-term success.

Scroll to Top

The Drug Deficiency Database tracks medication shortages, providing data on their scope and impact.

The Ministry of Industry and Trade tracks metrics like withdrawn medicines, citizen complaints, and expired drug sales to evaluate solution effectiveness.

Title:

Content: The Government has established the criteria for evaluating the effectiveness of the SMFA
31.08.2022
5: 35 PM
The government has established criteria by which it will assess the effectiveness of the system for monitoring the movement of medicines and other goods, including dietary supplements and disinfectants.
In particular, the effectiveness of the system in terms of the quality of medicines will be assessed by the number of medicines withdrawn from circulation, the number of citizens' complaints about violations and the number of expired drugs sold in pharmacies.
Photo: Artem Kosenok
In Russia, established criteria for assessing the effectiveness of the system for monitoring the movement of drugs (MDLP) and other goods, including dietary supplements and disinfectants.
The corresponding Order of the Government of the Russian Federation No. 2444 dated August 27, 2022 is published on the official portal of legal information.
It will be evaluated at the level of the state, the market and consumers.
Thus, the effectiveness of the system in terms of the quality of medicines will be assessed by the number of medicines withdrawn from circulation, the number of citizens' complaints about violations and the number of expired drugs sold in pharmacies.
According to the document, the Ministry of Industry and Trade until October 1 should publish on its official website the target annual values of the indicators provided for by the lists approved by this order for 2022-2025.
By continuing to use our site, you consent to the processing of cookies that ensure the correct operation of the site.

Key performance indicators (KPIs) are established to evaluate outsourced services through communication, site visits, audits, and performance reviews.

Title:

Content: How to monitor outsourced services?

Outsourcing services has become a common practice for businesses looking to streamline operations, cut costs, or tap into specialized expertise. Whether it’s outsourcing IT support, customer service, or manufacturing processes, monitoring these outsourced services is crucial to ensure they meet quality standards and deliver the desired outcomes. In this article, we will explore different strategies and tools that can help businesses effectively monitor their outsourced services and ensure successful partnerships.

The Importance of Monitoring Outsourced Services

Effective monitoring of outsourced services is essential for several reasons. Firstly, it allows businesses to maintain control over the outsourced activities, ensuring they align with their overall goals and objectives. Monitoring also helps in identifying and rectifying any potential issues or discrepancies before they escalate and impact the business negatively. Additionally, monitoring can provide valuable insights into the performance and effectiveness of the outsourcing partner, helping businesses make informed decisions about continuing or altering the outsourcing arrangement.

How to Monitor Outsourced Services?

Monitoring outsourced services requires comprehensive planning and the utilization of appropriate strategies and tools. Here are some effective ways to monitor outsourced services:

1. Clearly define expectations and objectives: Start by setting clear goals, performance metrics, and expectations for the outsourced services. This will provide a benchmark for monitoring and evaluating the service provider’s performance.

2. Establish key performance indicators (KPIs): Identify and agree upon specific KPIs that will be used to measure the outsourcing partner’s performance. These KPIs should be aligned with the business goals and provide quantifiable data for evaluation.

3. Regular communication and reporting: Establish regular communication channels and reporting mechanisms to stay updated on the progress of the outsourced services. This can include weekly or monthly meetings, progress reports, or dashboards.

4. Site visits and audits: Conduct periodic site visits or audits to assess the operational processes and quality standards followed by the outsourcing partner. This hands-on approach allows for a deeper understanding of their performance and helps identify any potential gaps or areas for improvement.

5. Performance reviews and feedback: Conduct regular performance reviews with the outsourcing partner to discuss their achievements, areas of improvement, and feedback. These reviews can provide an opportunity to align expectations, address concerns, and maintain a healthy working relationship.

6. Utilize technology: Leverage technology-driven tools and software to facilitate the monitoring process. These can include project management systems, performance tracking software, or customer relationship management (CRM) tools to ensure seamless collaboration and real-time visibility.

7. Define escalation procedures: Clearly define escalation procedures and points of contact for raised concerns or issues. This ensures a swift response and resolution to any problems that may arise during the course of the outsourced services.

Frequently Asked Questions (FAQs)

1. How can I ensure quality control in outsourced services?

To ensure quality control, clearly define quality standards and expectations upfront, incorporate quality checkpoints within the outsourcing agreement, and conduct regular audits.

2. Should I monitor all activities outsourced?

It’s essential to prioritize activities based on their impact on overall business objectives and risk factors. Focus monitoring efforts on critical and high-risk activities.

3. Can outsourcing partners provide their own performance metrics?

Yes, outsourcing partners can provide their own performance metrics, but it’s important to align them with the business’s objectives and ensure they effectively measure the desired outcomes.

4. How can I measure the ROI of outsourced services?

Measuring the ROI of outsourced services involves comparing the costs associated with the outsourcing arrangement against the benefits achieved, such as cost savings, improved efficiency, or increased revenue.

5. What if the outsourcing partner fails to meet the defined KPIs?

In such cases, it’s crucial to address the issue promptly. Identify the root cause of the performance gap, discuss it with the outsourcing partner, and establish a corrective action plan.

6. Are there any risks involved in outsourcing?

Yes, outsourcing comes with inherent risks such as data security breaches, communication gaps, or service quality issues. Monitoring helps identify and mitigate these risks.

7. How can I ensure data security in outsourced services?

Ensure the outsourcing partner has robust data security measures in place, sign non-disclosure and confidentiality agreements, and regularly assess their compliance with data protection regulations.

8. Should I rely solely on automated monitoring tools?

While automated monitoring tools can provide real-time data and alerts, combining them with regular communication, site visits, and performance reviews is recommended for a holistic monitoring approach.

9. How often should I conduct performance reviews?

The frequency of performance reviews depends on the nature and duration of the outsourced services. Generally, quarterly or biannual reviews are considered appropriate.

10. How can I foster a strong relationship with the outsourcing partner?

Maintain open lines of communication, encourage collaboration, offer constructive feedback and recognition for achievements, and involve the outsourcing partner in the decision-making process.

11. Can outsourcing partners self-monitor their services?

Outsourcing partners can self-monitor their services, but an independent monitoring process from the client’s side adds an extra layer of assurance and facilitates performance evaluation.

12. When should I consider terminating an outsourcing agreement?

Terminating an outsourcing agreement may be necessary if the outsourcing partner consistently fails to meet KPIs, breaches contractual obligations, or if the business objectives are no longer aligned.

Scroll to Top

Quality management tools provide real-time data to enable prompt issue resolution and quality improvement decisions.

Benchmarking and corrective action processes ensure effective and efficient solutions to medication shortages.

The FDA blames supply chain gaps and downtime for shortages, citing a need for better metrics.

Lack of transparency hinders response to drug shortages, making it essential to track metrics like the number and duration of shortages.

The average shortage affects at least half a million patients, highlighting the need for effective solutions.

Medication shortages cost facilities at least $359 million per year.

Title:

Content: Skip to content

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology …

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology …

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication … It is estimated that drug shortages are costing facilities at least $359 million per year in … More than 50,000 institutional and retail pharmacies across North America …
See all stories on this topic

Nearly 75 per cent of Ontario doctors experienced burnout during pandemic, survey says …

Nearly 75 per cent of Ontario doctors experienced burnout during pandemic, survey says … as COVID-19 was first hitting North America – that saw 66 per cent of respondents report some level of … Dr. Adam Kassam, president of the OMA, said physician burnout has always been a problem, but it’s been …
See all stories on this topic

Health researchers report funder pressure to suppress results – Nature

These trials, published between 2007 and 2017, were cited in Cochrane reviews, which are considered the ‘gold-standard’ of evidence used to inform …
See all stories on this topic

Survey: nearly 75 per cent of Ontario doctors experienced burnout during pandemic – Toronto Star

Dr. Carolyn Snider felt a gamut of emotions while working in one of the busiest emergency rooms in Canada during the last 18 months of the …
See all stories on this topic

Asia-Pacific Over the Counter (OTC) Drugs Market 2021 Segmented by Product, Distribution …

North America currently holds the largest share in the market, due to the increasing expenditure in healthcare. Inclination of Pharmaceutical Companies …
See all stories on this topic

Published inSubstance Abuse

Drug use evaluation is a key component of pharmacy quality management, aiming to improve care quality and prevent adverse interactions.

Title:

Content: Egypt News
Healthcare: Drug Use Assessment as a Pillar for Implementing Pharmacy Quality Management Programs
Thank you for reading the news about health care: Evaluation of drug use is a pillar of the implementation of pharmacy quality management programs and now with the details
The General Authority for Health Care announced the establishment of a unit to evaluate the use of drugs and drug appropriateness to improve the quality of care and the effectiveness of drugs in general and reduce the misuse and abuse of drugs, in accordance with the decisions of the Board of Directors of the Authority, headed by Dr. Ahmed Al-Subki, Assistant Minister of Health and Population and General Supervisor of the Comprehensive Health Insurance Project. Egyptian medicine.
Dr. Sherif Kamal, Advisor to the President of the Health Care Authority for Pharmaceutical Affairs and Drug Management and Director of the Department of Medicine and Pharmaceutical Affairs at the Authority, pointed out that the Unit aims to improve the quality of care and drug effectiveness in the health facilities of the Authority in the governorates of the Comprehensive Health Insurance, prevent adverse drug interactions, encourage the practice of using clinically appropriate and effective drugs.
He explained that the pharmacist as an essential part of the health team participates in the development of the treatment plan and follow up its implementation with the patient or the nursing team, where he reviews the doctor 's prescription to ensure the appropriateness of the drug to the patient in terms of "reasons for use, dosage, frequency of dose, method of administration". Individual or group of patients or level of exchange and inventory.
He added that the drug use evaluation program is an approved, organized and continuous system to improve the quality of drug use in health facilities, noting that the drug use is evaluated using a set of predefined criteria, with efforts to correct usage patterns that do not conform to these standards, and includes a mechanism to measure the effectiveness of corrective actions to promote optimal, appropriate, safe and effective use of drugs.
He added that drug use assessment is a comprehensive and dynamic process of review, evaluation and intervention, which includes two main stages working in an iterative cycle, the first phase "survey" includes measuring and defining drug use, identifying drug use problems, measuring the impact of interventions, and the second phase "intervention" where problems are solved, building scientific consensus on guidelines, and implementing corrective actions to improve drug use and effectiveness.
Dr. Sherif Kamal stressed that the drug use evaluation system is a key pillar to provide pharmacy service, clinical pharmacy practice, pharmacy quality assurance and management programs, to ensure that the patient has the highest therapeutic effectiveness and the least side effects and to maintain the patient ’ s quality of life. Then cure the disease.
You may also read.

A unit evaluates drug use against predefined criteria, measuring effectiveness and correcting non-conforming usage patterns.

Title:

Content: Egypt News
Healthcare: Drug Use Assessment as a Pillar for Implementing Pharmacy Quality Management Programs
Thank you for reading the news about health care: Evaluation of drug use is a pillar of the implementation of pharmacy quality management programs and now with the details
The General Authority for Health Care announced the establishment of a unit to evaluate the use of drugs and drug appropriateness to improve the quality of care and the effectiveness of drugs in general and reduce the misuse and abuse of drugs, in accordance with the decisions of the Board of Directors of the Authority, headed by Dr. Ahmed Al-Subki, Assistant Minister of Health and Population and General Supervisor of the Comprehensive Health Insurance Project. Egyptian medicine.
Dr. Sherif Kamal, Advisor to the President of the Health Care Authority for Pharmaceutical Affairs and Drug Management and Director of the Department of Medicine and Pharmaceutical Affairs at the Authority, pointed out that the Unit aims to improve the quality of care and drug effectiveness in the health facilities of the Authority in the governorates of the Comprehensive Health Insurance, prevent adverse drug interactions, encourage the practice of using clinically appropriate and effective drugs.
He explained that the pharmacist as an essential part of the health team participates in the development of the treatment plan and follow up its implementation with the patient or the nursing team, where he reviews the doctor 's prescription to ensure the appropriateness of the drug to the patient in terms of "reasons for use, dosage, frequency of dose, method of administration". Individual or group of patients or level of exchange and inventory.
He added that the drug use evaluation program is an approved, organized and continuous system to improve the quality of drug use in health facilities, noting that the drug use is evaluated using a set of predefined criteria, with efforts to correct usage patterns that do not conform to these standards, and includes a mechanism to measure the effectiveness of corrective actions to promote optimal, appropriate, safe and effective use of drugs.
He added that drug use assessment is a comprehensive and dynamic process of review, evaluation and intervention, which includes two main stages working in an iterative cycle, the first phase "survey" includes measuring and defining drug use, identifying drug use problems, measuring the impact of interventions, and the second phase "intervention" where problems are solved, building scientific consensus on guidelines, and implementing corrective actions to improve drug use and effectiveness.
Dr. Sherif Kamal stressed that the drug use evaluation system is a key pillar to provide pharmacy service, clinical pharmacy practice, pharmacy quality assurance and management programs, to ensure that the patient has the highest therapeutic effectiveness and the least side effects and to maintain the patient ’ s quality of life. Then cure the disease.
You may also read.

The Ministry of Health and Prevention has launched an AI center of excellence for strategic drug inventory management and tracking medicine shipments.

Title:

Content: Gulf News / UAE News
UAE | « Health » launches the first center of excellence in artificial intelligence
• 1 / 2
• 2 / 2
Thank you for reading the news about « Health » launches the first center of excellence in artificial intelligence and now we start with the details
Sharjah - By Ayman Al Fateh - The Ministry of Health and Prevention (MOHAP) has launched the first center of excellence in artificial intelligence in the health sector in the UAE, with the aim of promoting digital transformation in the field of health data, employing smart technologies to develop the efficiency and quality of its services, and establishing an integrated digital services system that will delight customers and provide them with the best sustainable and innovative services.
The Ministry revealed that the competence of the Center of Excellence, which was allocated to manage Emirati cadres in cooperation with data analysis experts from SAS, will cover seven areas, including licensing medical facilities, where artificial intelligence will be used to facilitate the selection of sites to build hospitals or medical centers, by linking the results of these analyzes to investors before submitting license applications for medical facilities.
Doctors will also be supported in securing the necessary licenses according to the needs of the State.
It also includes the Donation and Transplantation Center to match tests between donors and patients, which helps to facilitate organ transplants and give priority to critical cases inside and outside the country.
Artificial intelligence will also be used to analyze the results of radiological examinations, increasing the efficiency of diagnosing cases.
It also includes the launch of an artificial intelligence laboratory in December, in addition to the field of strategic drug inventory management, using artificial intelligence to link databases and use analysis to develop distribution strategies according to the necessary needs.
It tracks the shipment of medicines from the manufacturing country until they are delivered to patients, with links to other systems in the country.
The center of excellence will enhance the analysis of birth and death data, helping to better understand the causes and analyze the data.
He also plays a prominent role in the management of the Ministry ’ s Crisis, Emergency and Disaster Center.
As well as managing information security and big data analysis, which contributes to enhancing cyber security in the ministry ’ s network.
Assistant Undersecretary for the Support Services Sector, Ali Ahmed Al-Dashti, said that the launch of the center comes within the ministry ’ s vision to develop digital services through the integration of the latest technologies in services, including artificial intelligence, big data and cloud computing, in line with the National Strategy for Artificial Intelligence 2031 and the aspirations of the UAE Centennial 2071.
He pointed out that the establishment of the Center of Excellence for Artificial Intelligence (COE) is part of a joint project between the Ministry and SAS, which specializes in data analysis and artificial intelligence, in line with the leadership ’ s vision to take advantage of the latest technological innovations by employing big data to help predict information and make more effective decisions. Artificial Intelligence 2031.
Samir Al-Khoury, Acting Director of Smart Health Department, said that the center will develop high-quality analytical and predictive models in its operations by taking advantage of artificial intelligence applications and advanced data sources, in order to provide reliable and high-quality analysis and research that contribute to improving the customer experience.
Stay up to date with our latest local, sports, political and economic news via Google news.
Share
Facebook Twitter LinkedIn Pin Interest Whats App
Advertisements
You may also read.

AI is used to analyze birth and death data to understand causes and make informed decisions.

Predictive analytics and AI can mitigate and solve supply chain difficulties.

Title:

Content: Analytics and AI in 2022: Innovation in the era of COVID

This year's predictions focus less on analytics technology per se and more on its application to address pandemic-driven phenomena.

As we have reached the end of 2021, my inbox has become stuffed with the now customary batch of emails, from tech companies and their PR agencies, sharing management's thoughts on what next year will hold for us, in the world of data, analytics and AI. As ever, the annual exercise of compiling sage predictions about the upcoming year, from executives around the industry, was a big effort. In fact, once all the prediction emails were consolidated, a 50-page document resulted. As with any big data exercise, my goal was to aggregate the data into groupings I could organize it by, both to tame the volume of the data and because the groupings are themselves instructive.

This year, most of the predictions were not about particular technologies, like Hadoop, Kafka or Spark. And they weren't even about tech genre issues like the battle between data warehouses and data lakes. Instead, this year's predictions (for next year) focused on broader business or even societal issues, many of which stem from the world's collective experience of the Coronavirus/COVID-19 pandemic and the changes it has imposed.

Technology's in there, of course; for example, there was a lot of discussion of artificial intelligence (AI), low code/no code platforms and architectural approaches to analytics, like Data Fabric and Data Mesh. But issues pertaining to supply chain disruptions; labor shortages and the "great resignation;" and the interplay between customer experience management, personalization and data protection had huge presence as well.

Let's explore a grouped summary of the predictions.

Supply Chain

We all know the pandemic has had a knock-on effect of impacting global supply chains. For business, that has meant disruption and flux. Interestingly, many of our prediction participants saw this as a tech challenge. As unpredictable as supply chain issues might make things feel, many predictions were based on the premise that predictive analytics could mitigate the the difficulties, as long as the models themselves were carefully monitored for accuracy and drift.

"Many industrial companies...over the last two years...were forced to rely on AI and other digital technologies to solve urgent, real-world problems in supply chains and production" said Artem Kroupenev, VP of Strategy at Augury. Nick Elprin, CEO, Domino Data Lab, feels "the continued volatility of unpredictable business factors, from supply chains to extreme weather, will greatly accelerate the need for businesses to continuously monitor how well their models reflect the real and rapidly changing world of their customers."

Alok Ajmera, CEO of Prophix, opines "Businesses have seen their share of disruptions over the last year, and in 2022 they most likely will continue to deal with the impact of supply chain shortages, rising inflation, and increased cyber security threats...Cloud-based "if/then" scenario planning software tools [enable]...continuously reset forecasts...according to real time data insights to meet fluid market conditions."

Beware, though. Supply chain issues don't just impact material goods; they can impact the technology we tend to view as infinite and always available, too. With that in mind, Lenley Hensarling, chief strategy officer at Aerospike, said "Supply chain issues, both hardware and personnel, will continue with the cloud..as companies continue to migrate to the cloud in 2022, they'll be surprised to find hardware and personnel shortages that may force them to alter their plans."

You can't fire me, I quit

And speaking of the personnel shortages, many of our predictors had something to say about "the great resignation," 2021's apparent voluntary exodus of workers from their jobs. For example, Buno Pati, CEO of Infoworks says that we should "consider [the great resignation's] particular implications regarding scarce data engineering and data science talent, already in very high demand and commanding significant compensation." In other words, finding good data pros was bad before, and it's getting even worse. As to a solution, he predicts that "in the coming year, adoption of new automated approaches to data operations and orchestration will free this critical talent pool from the mundane and focus these valuable professionals on creating and delivering business value."

Momentive (formerly SurveyMonkey) CIO, Eric Johnson, agrees that automation can help address the shortage and work as a retention tool to keep existing employees happier: "in 2020, 31% of companies had at least one system automated. With the great resignation and demand for better quality jobs, automation will accelerate immensely to remove monotonous processes and ensure employees have high-quality work experiences with diverse and meaningful tasks." Speaking to that notion of quality, Johnson also says "The Great Resignation has shown that pay is no longer a main retention lever. Employees are instead eager to have the working environment they want and new challenges that keep them improving and learning as individuals and professionals."

There's an AI angle here too. Nick Curcuru, Vice President of Advisory Services at Privitar, says "analytics in HR has traditionally been about reporting. As organizations grapple with employee turnover amidst the 'Great Resignation,' they will increasingly look to predictive analytics to help save the day." Gleb Polyakov, co-founder and CEO of Nylas, says "Advancements in AI combined with the labor shortage and demand for rapid scale have forced companies to automate wherever possible." Polyakov doesn't predict a dystopian situation though, assuring us that "...even with continued AI-led innovation, humans will continue playing an essential role in true organizational impact, analysis, and growth."

Of fabric, and mesh

Beyond societal issues, architectural ones have been important this year too, especially those that can help companies leverage their analytics investments more successfully. Leading contenders here are the Data Mesh and Data Fabric approaches and many of this year's predictions focused on them.

To begin with, Steve Totman, Chief Strategy Officer at Privitar, believes that "Organizations are increasingly embracing data mesh and data fabric methodologies as the basis of their modern data stacks." Infoworks' Pati is right there with him and thinks that "2022 will see significant growth and interest in data fabric solutions as companies seek to leverage a common management layer to accelerate analytics migration to the cloud, ensure security and governance, quickly [and] deliver business value..." On behalf of the company, he states "we believe this technology will be broadly adopted over the next five years."

Totman and Pati are not alone. "'Data fabric' will be a popular buzzword." was one of five big predictions from Mark Van de Wiel, VP of Technology at HVR (now owned by Fivetran). And Ravi Shankar, SVP and CMO at Denodo, headlines his #1 predicted trend as "Data fabric becomes the foundation for the distributed enterprise," adding that "by enabling organizations to choose their preferred tools, these data fabrics will reduce time-to-delivery and make it a preferred data management approach in the coming year."

Haoyuan Li, founder and CEO of Alluxio, sees Data Fabric as more than popular...he views it as a solution to the new round of data silos: "with SaaS and managed services in the cloud creating data silos, improved governance and catalog with a data fabric spanning multiple services will come to the rescue in 2022." Komprise president Krishna Subramanian sees a similar silo-busting value proposition, stating that "IT and storage managers will choose data fabric architectures to unlock data from storage and enable data-centric vs storage centric management."

Sure seems there's a lot of hope riding on these architectures. I wonder what next year's experts will say about that.

No/Lo-Co

We've already mentioned automation as a partial antidote to the labor shortage, and many of our predicting personnel see low-code/no-code platforms -- in many ways, automation's partner -- as a huge force for efficiency and change in 2022.

Christine Spang, co-founder and CTO of Nylas, predicts, given the "Engineering Labor Shortage, Low-Code Development Takes Off," and expounds on that headline by saying "we'll see the adoption of low-code, no-code tools and applications accelerate in 2022 and beyond."

Venkat Thiruvengadam, the founder and CEO of DuploCloud, explains: "no-code/low code platforms enable non-technical business experts to create software in the domains they know best, without requiring coding knowledge. Experts who were previously locked out of a business idea because they lacked the coding expertise can now get started with minimal coding knowledge." He adds that "the DevOps skills shortage will only continue to grow, accelerating the need for no-code / low code solutions."

But Gil Hoffer, Co-Founder and CTO of Salto, addresses the flip side of that DevOps observation, believing that no- and low-code will acquire attributes of conventional software: "as no code and low code platforms and tools become more pervasive, methodologies and tools from the software development and DevOps worlds, such as automation, version control and declarative languages will be applied and added to these environments."

DevOps-hungry or not, Mendix CEO Tim Srock and his team think "low-code will move past app development" and feel it will grow to "include customer experience design and intelligent workflow automation." The Mendix gang also feels that "...companies will use low-code to automate tasks within workflows." And Ryan Welsh, Founder and CEO of Kyndi, thinks low- and no-code will move into the AI realm too, predicting that "Universal AI will be embedded in a suite of configurable business solutions that do not require coding."

But how long can low/no...go? Since the advent of CASE (computer-aided software engineering) in the 1980s, we've seen platforms that require minimal programming have huge appeal. We've also seen the pendulum swing back the other way, where code-first platforms, and the skill sets needed to drive them, migrate back into high demand.

Personalized, but not surveilled

From low-code, we move to what we might call "low-data." Dr. Jans Aasman, CEO of Franz Inc., characterized the new normal of personal data analytics: "in 2022 we will see new ways for users to regain control of their data." That's great, but it's yet another disruption, forcing companies to personalize experiences without access to as much personal data. Jennifer Krizanek, President, NA and CMO of Contentserv, describes the challenge: "2022 will witness businesses strategizing on how to personalize the customer experience without breaking GDPR laws or infringing on consumers' data privacy rights." She further opines that next year "will be the year in which businesses learn how to operate, market and personalize their offerings to consumers without tracking their every move."

But how can that be done? For openers, Denodo's Shankar says that "in 2022, organizations will leverage small data analytics to create hyper personalized experiences for their individual customers to understand customer sentiment around a specific product or service within a short time window." That makes sense, but the requirement still seems formidable.

AI, as it turns out, may be the key to doing more with less. "With machine learning, companies can optimize, automate, and personalize content and message delivery timing to increase engagement rates at the personal level" says Jason VandeBoom, CEO of ActiveCampaign. And that's not just a nice-to-have according to Mendix folks. Rather they see it as a must-have: "Hyper-personalization will become the norm: As the world becomes increasingly digital, customers will expect experiences that are tailored and can adapt to their needs and desires in the moment. To do that, applications need to take advantage of AI versus executing simple rules."

Vertical AI

AI isn't just for personalization though. In fact, the sense of the predictors' room is that vertical industries, from finance to healthcare, will benefit from AI in 2002. Ajmera at Prophix headlines one of his predictions as: "The Era of AI-Powered Corporate Finance Is Here." His analysis says "...as businesses emerge from the volatile pandemic period, expect to see CFOs finally taking the plunge into AI-powered finance technologies, kickstarting the next era of super-charged corporate finance." Franz's Aasman says "This 'Total AI' is swiftly becoming necessary to tackle enterprise scale applications of mission-critical processes like predicting equipment failure, optimizing healthcare treatment, and maximizing customer relationships."

Further along the healthcare road, Dave Wessinger, CEO and Co-Founder, PointClickCare, believes that "in 2022 we should expect to see more healthcare organizations capitalize on artificial intelligence (AI) to monitor patient behavior, overall creating a safer environment for patients and powering healthcare staff to provide more streamlined and better care." It's not just AI, either. Todd Gottula, President, Clarify Health, thinks analytics will come along for the ride: "Payers, providers, and life sciences companies will turn to on-demand analytics software that gives them instant access to a 360-degree view of the patient journey and a window into how medical care and social and behavioral determinants of health interconnect to influence outcomes."

Transformation can be fun

Virtually everything we've looked at so far pertains to digital transformation, even if only implicitly. But how well have such "DX" efforts gone this far? Not far enough, in the view of Contentserv's Krizanek, who "...believes in 2022, organizations will extend earlier digital transformation efforts but, in doing so, will be forced to rely on their ability to automate trusted data delivery."

To get there, AI comes to the rescue, again. Komprise's Subramanian believes "AI and machine learning in the cloud continue to deliver more capabilities for customers and are becoming core enablers of digital transformation." Subramanian believes it's less not only about AI though. Companies' jettisoning their proclivity to be data pack rats is another factor: "Zombie data or dead data will garner proper attention as enterprises aim to better segment, classify, organize, cleanse, manage and justify spending on storage, backup and DR. Data hoarding will come to an end as part of successful digital transformation initiatives."

SingleStore's Oliver Schabenberger thinks DX success is a data storage technology issue, and one that will be solved in a couple of years: "By 2024, data technology will have evolved to allow organizations to optimize for frictionless digital transformation rather than optimize for read/write of transactions or efficient scans of large datasets. Databases will be an active participant and orchestrator of decision support." Given the company's combination of row store and column store technology in one database, this vantage point makes sense.

Don't just innovate, operate

Overall, while they don't come right out and say it, our clairvoyants seem to see 2022 as a year of fit-and-finish, rather than one of raw innovation. We already have tons of great analytics and intelligence technology, and we have, for a few years now, understood their potential collective transformative power. What we have largely neglected, though, is achieving high rates of success in implementing these technologies and making them operational. With the economic and logistical impacts of the COVID pandemic, that's now moved from being suboptimal to being inexcusable.

Now we need to take stock of what we have, slow down on adding to it and ramp up on the discipline necessary to exploit it to its full potential. Our prognosticators think that will happen in 2022. My guess is it might take longer, but it's a good omen that people have apparently been pondering it so fully in the latter part of 2021.

Cloud-based tools and data approaches leverage analytics investments for planning and forecasting.

Low-code and no-code platforms increase efficiency and create personalized customer experiences without surveillance.

AI optimizes content delivery for hyper-personalization, benefiting industries like finance and healthcare.

In 2024, 323 US drugs, mostly non-patented sterile injectables, faced shortages.

Title:

Content: Meitu
The first quarter of the United States serious drug shortage 323 drugs urgent cancer patients also have to be diverted and rationed!
CHU HENG NETWORK NEWS CENTER 2024-04-16 10: 42
According to the latest data from the American Society of Health System Pharmacists (ASHP) and the Utah Center for Drug Information Services, a total of 323 drugs in the United States were in severe shortages in the first quarter of this year, surpassing the record of 320 in 2014.
Among the drugs affected are the widely used diabetes drugs Ozempic and Mounjaro, the allergy treatment drug adrenaline, the common antibiotic amoxicillin for children, chemotherapy drugs and injections commonly used in hospitals in intensive care.
ASHP CEO Paul Abramowitz said in a statement that almost all categories of drugs are facing shortages, with non-patented sterile injectable drugs, including cancer chemotherapy drugs, and emergency drugs stored in hospital emergency vans and operating areas, the shortage of such drugs is the most worrying.
According to the American Cancer Society, chemotherapy is one of the top five drugs most affected by the shortage, which threatens to have a devastating impact on patients, and some hospitals and clinics say doctors have had to divert patients to ration their medications because of a shortage of some chemotherapy drugs.
In addition, ASHP noted that the continued nationwide shortage of ADHD drugs is “a problem for clinicians and patients. ”
The shortage of popular drugs is even more acute, with Mounjaro, the diabetes drug known as the “slimming pill ”, already in dire straits.
In response, Lilly said that the “unprecedented surge in demand ” for Mounjaro and its similar drug Zepbound has led to a shortage in the market, which the company is struggling to cope with.
Lilly is ramping up investments to boost production at Mounjaro and Zepbound in the second half of 2024.
The company said it expects intermittent supply disruptions in the near term due to unprecedented demand.
How to cure the drug shortage
The last major “drug shortage ” in U.S. history occurred in 2014, and it has only been alleviated in the years since.
Since 2021, the drug shortage situation seems to be increasing, and scholars in the field of medical health and economics in the United States believe that the reason for most drug shortages in the United States is the fragmentation of the drug supply chain.
The White House this month proposed spending between $3.26 billion and $5.11 billion over the next decade to help address the nation ’ s drug shortage.
The bill requires approval and funding from the U.S. Congress.
U.S. researchers and policymakers believe that a complete solution to the “drug shortage ” may require changes to the business model of the U.S. pharmaceutical industry, including measures to increase the price of generic drugs to attract more drug manufacturers.
Policymakers recommend giving the FDA more power to access more information about drug shortages and impending shortages.
Currently, the FDA relies primarily on phone calls to manufacturers asking if they can increase their supply to understand the situation.
The American Society of Health System Pharmacists said it is working with the federal government to advise the government on measures to address the drug shortage, including that Congress should require manufacturers to be more transparent on any supply chain issues and encourage more diversity in supply chains.
According to Abramowitz, “The federal government still has a lot of work to do to fundamentally address drug shortages, and the American Society of Health System Pharmacists will continue to engage regularly with policymakers to guide them in drafting and passing new legislation to address drug shortages and continue to advocate vigorously for proven solutions on behalf of our members. ”

Chemotherapy and ADHD drugs were among those affected by shortages.

Lilly increased Mounjaro production, but US drug shortages worsened since 2021 due to supply chain issues.

The White House proposed $3.26-5.11 billion to address drug shortages, which the FDA currently tracks through manufacturer phone calls.

Covid-19 has accelerated company digitization 20-25 times, except in biotech and pharma, which are hindered by regulatory requirements.

Title:

Content: BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

Analytics And Insight: Digging Into Data

Kathleen Brunner is the founder, current CEO and President of Acumen Analytics.

While there is cautious optimism, the pandemic continues to impose pressure points and challenges requiring us to change the way we do things. This period in time calls for us to significantly broaden our thinking.

The need for collaboration in organizations has never been more apparent, and the challenges of collaboration never greater. Eliminating departmental working silos is only the beginning. The entire ecosystem needs to be strung together in a secure yet frictionless communication framework, allowing a connected data flow and integrated view of data to achieve the ultimate strategic plan, speed to market and overall success. This need was greatly amplified throughout the pandemic and specifically across life sciences industries. One spotlighted area is pharmaceutical supply chain practices, business continuity and drug/supply shortage prevention.

But many leaders are wondering: How can my organization be future-ready?

The biotech and pharma spaces are often lagging in adopting new technology for a variety of reasons, often due to regulatory and validation requirements. While not specifically focused on life sciences, a recent McKinsey study indicates one silver lining of the Covid-19 crisis is that companies appear to be digitizing many activities 20-25 times faster than previously observed.

Data

Data is being generated rapidly all around us. But, proper use, interpretation and understanding of this data is required for efficiency and successful outcomes. Industry 4.0 deepens the need for companies to ask the right questions regarding their data. In the biopharma world, technical changes are a crucial component of prosperity. Edge computing and smart manufacturing allow for more equipment to be digitally enhanced and cloud-enabled. Temperature monitoring of a shipment from factory to pharmacy is a great example of this.

Additional investments in technology are key to the education and implementation of systems capable of handling high data volumes through experiments that produce large data sets (i.e., metabolomics). After all, data can be meaningless if not interpreted correctly. Success can be achieved by following the lead of other industries that have shifted away from a "this is how we have always done it" mindset.

Digital Transformation

But why all this talk about digital transformation now? Executives are being pressed daily that they need to "go digital." It's transform or be left behind.

This is not new; ERP systems began this process in the 1990s. But what does digital transformation really mean? It is not just about technology; it's about rethinking the current, often longstanding processes with a new approach where technology is not the driver but rather the enabler — new ways through evolution and innovation to change customer, vendor, employee experience. It is a mindset of continuous improvement, a shift to include more data, faster, from more devices (e.g., wearables, sensors, watches, machines, etc.) to reduce risk and increase insights by transforming data into intelligent decision-making. This includes artificial intelligence (AI), machine learning (ML), robotic process automation (RPA), blockchain and the Industrial Internet of Things (IIoT).

Bottom Line

The key to success will be to understand where and what technology is relevant and what to invest in. Lack of clarity could prove to be expensive, wasting effort and resources and potentially impeding organizational success.

Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Follow me on Twitter or LinkedInCheck out my website

Edge computing and smart manufacturing enhance equipment digitally, including temperature monitoring of shipments.

Digital transformation involves rethinking processes using artificial intelligence and machine learning to inform decision-making.

AI is used in supply chain management and healthcare for automation, predictive analysis, disease detection, and patient flow management.

Title:

Content: BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

Artificial Intelligence Stocks: The Top 9 AI Investment Opportunities

Following
New! Follow this author to stay notified about their latest stories.
Press play to listen to this article!

Key Takeaways

  • Artificial intelligence impacts every aspect of our lives, from our search engine results to how our products get delivered, photo apps, face ID, and on, and on.
  • There are many opportunities for investing in AI right now as companies worldwide look to capitalize on this technology.
  • Some insurance companies are now fully backed by AI, and there are even AI investment apps available to the average investor now.

Conceptually, AI is to the 2020s what DNA was to the 1990s, what bandwidth was to the early aughts, and mRNA was to the pandemic. You can’t ignore the power of artificial intelligence because it’s part of everyday life now. AI is designed to perform typical tasks involving some degree of problem solving and decision making that humans would normally do. Those tasks now range from making decisions regarding an insurance claim all the way to creating images from scratch based on text prompts.

Many new uses of artificial intelligence, the technology, are still being discovered. Yet, if you think about the evolution of services like Siri or Alexa in our everyday lives, it’s here too.

For today, we’ll look at the best artificial intelligence stocks so you have some investment opportunities to consider if you’re a proponent of this space.

How can you invest in Artificial Intelligence?

While there are many different ways to invest in AI, it is typically a layer of a company’s tech stack, there’s still no clear AI company the way Google was the search engine or Tesla is electric. Here are the investable industries employing substantive AI right now.

Financial Services

Financial services rely on AI-powered technology for fraud detection, underwriting loans, customer service, algorithmic trading, and everyday banking services to simplify processes for customers.

Algorithmic trading is one area that fascinates us here because this technology is being used to minimize transaction costs, improve order execution, and minimize human errors involved in trading securities. As we all continue to look for risk reduction in a volatile stock market, it's worth noting that the algorithmic trading industry will be worth up to $19 billion annually by 2024.

Actual AI investing, where the neural networks are assessing markets, not just running complex algorithms, is rarer still. Q.ai’s artificial intelligence scours the markets for the best investments for all manner of risk tolerances and economic situations. Then, it bundles them up in handy Investment Kits that execute specific investment strategies like shorts and pair trades.

Healthcare

AI is being used in healthcare in a number of ways, though most of the applications have to scale fully, from tools that can detect diseases and review images like xrays and scans to managing patient flow to recommending next best actions.

Since healthcare is such a data-driven field, AI’s role is growing rapidly. AI can also be used for recognizing medical images, streamlining workflow with physicians and hospital staff, and providing administrative assistance. The World Economic Forum even confirmed that AI could help detect tuberculosis, which would be a significant breakthrough for society.

Insurance

Insurance companies are starting to rely on the power of AI for help with many aspects of the business, from the administrative registration process to handling insurance claims. Lemonade is the first insurance company that’s entirely powered by AI.

Supply chain management

While we keep hearing about supply chain issues in the news, it’s worth mentioning that many companies rely on AI to power the entire supply chain and logistics process. Here are some of the common examples of how AI is impacting supply chain management:

  • Supply chain automation, from document processing to chatbots for customer service management
  • Transportation automation, with many companies investing in autonomous trucks
  • Predictive analysis for more accurate forecasting
  • Quality control
  • Supplier relationship management

Advertising and media

We recently looked at how AI-based tools like DALL-E 2 and DALL-E Mini can create images based on text prompts to generate AI art. Advertisers are using the power of AI to predict customer demands, provide suggestions for users, and handle the entire shopping experience.

It’s also worth mentioning that industries like cybersecurity, information technology, and even retail shopping will continue to see AI-powered advances. Any company in one of these fields could be worth investing in if you’re looking for AI investment opportunities.

While some companies focus on creating AI-based services, there are many other companies that are simply focused on investing in AI to improve business operations. Many tech giants are selling AI analytical services to enterprise clients for sizeable contracts. These services related to AI can range from cloud computing to client software tools.

What are the best AI companies to invest in right now?

Here are the best companies to invest in right now if you’re looking to get into the AI space.

Alphabet Inc. ($GOOGL)

Google's parent company is one of the global leaders in AI research. You don’t have to look far to see the reach of Google’s AI technology as the search engine algorithm likely brought you to this article. AI is also used in every aspect of Alphabet’s business, from accurately organizing your photos to predicting where you want to travel with Google Maps.

While we’ve all seen the power of AI in Google, it’s worth mentioning that Alphabet recently purchased the AI startup Alter for $100 million. Alter is an avatar startup that helps creators and brands express virtual identities. Many analysts believe that this move was made to help Google compete with TikTok. This comes on the heels of the recent acquisition of Mandiant as Alphabet increases its investment in AI and cloud security.

Microsoft ($MSFT)

Microsoft uses AI-powered technology for a variety of its services, but they just announced the introduction of an AI-powered graphic design tool. Microsoft Designer will be a graphic design app in Microsoft 365 that will use the same AI technology found in DALL·E.

Microsoft’s Azure AI platform allows companies to create innovative AI services.

Palantir Technologies Inc. ($PLTR)

Palantir is a data analytics company that uses AI tools to help people make decisions based on better data analysis. This smaller growth company uses AI to analyze data and recommend decisions to a variety of customers. The Palantir Apollo is used for improving delivery systems and automating configurations. Palantir has even been named a leader in the field of AI platforms as the company’s software is used across 50 different industries. The company recently announced that it expects to report between $503 million and $505 million in revenue for the 4th quarter of 2022 as they continue to build the digital infrastructure required for continuous industrial progress.

Lemonade ($LMND)

This is the first insurance company fully powered by AI. When you check out the website, you’ll directly deal with “Maya,” the AI bot that will help you with every step of the process, from signing up for an insurance policy to filing a claim. Many users have turned to Lemonade because you can file an insurance claim in seconds without ever speaking to anyone about it.

Tesla ($TSLA)

Tesla is so dedicated to AI that the company holds an annual AI Day that’s used as a recruitment tool to attract the brightest minds in the field. Tesla has been teasing a humanoid robot, self-driving cars, and the idea of a robot taxi service that would be a mix of Uber and Airbnb as the company continues to focus on improvements in AI.

Amazon ($AMZN)

The entire company uses AI technology in some fashion, from forecasting customer demand to the Alexa device that can be found in many homes. Amazon uses AI at some fulfillment centers as robots work with human beings. The company then uses AI for product forecasting as it would be difficult to maintain inventory levels with such a wide variety of items available online. Amazon also utilizes chatbots for customer service functions to help make the entire shopping process smoother.

Additionally, Amazon Fresh and Amazon Go stores use the Just Walk Out payment system where you don’t have to deal with a human to check out your purchases.

Workday, Inc. ($WDAY)

Workday believes that AI is changing the way companies use HR analytics. The company helps larger firms with AI-powered and cloud-based HR services. The companies that use Workday are given analytics tools to help with making data-driven decisions and financial tools for budget planning. The company mainly uses AI for informed decision-making regarding staffing, insights on unlocking opportunities, and improving experiences so that workers can realize their full potential.

International Business Machines Corp. ($IBM)

IBM was actually at the forefront of AI-based technology when the Deep Blue supercomputer defeated chess champion Garry Kasparov back in 1997. IBM’s Watson has recently made headlines for its AI efforts as it’s used to predict future occurrences, optimize tasks, and help folks with time management.

IBM recently announced that they are training customer service robots to sound more human for improved connections. IBM offers conversational chatbots to business clients who want to improve customer service and digital experiences.

How Q.ai uses Artificial Intelligence

If you’re looking to see the power of AI in action, you don’t have to look any further than Q.ai. Our company is built to leverage artificial intelligence to offer investment strategies for those who don’t want to be burdened with the stress of trying to pick individual stocks. Q.ai utilizes artificial intelligence in three key ways to help investors:

  1. Creating Investment Kits. The power of AI is used to assess every investment every week and to bundle them into kits that users can use to invest with specific parameters. Investors can choose kits like Precious Metals, Tech Rally, Value Vault, and Short Squeeze. You don’t have to worry about deciding which individual securities to invest in or how they should be weighted within your portfolio — the AI does it for you.
  2. Mitigating risk. AI weights the assets in each Investment Kit to reduce the risks for users, a truly unique and highly effective application for the everyday investor.
  3. Handle volatility. Portfolio Protection helps you weather the ups and downs in the market due to the uncertainty in the world right now. This feature uses AI predictions to forecast possible risks and adjust portfolio allocations.

If you’re hoping to make money in the AI space, you can invest in one of our Investment Kits. AI-powered Investment Kits take the guesswork out of investing so you don’t have to worry about where your money’s going.

Bottom Line

It will be fascinating to see how the power of AI technology will be used in more aspects of our daily lives. But there are many different ways that you can invest in AI today. According to Zion Market Research, the global AI industry should grow to $422.37 billion by 2028, increasing from $59.67 billion in 2021. Because AI touches so many parts of business in multiple industries, the question is not whether to invest in AI, only where.

Download Q.ai today for access to AI-powered investment strategies.

Follow me on Twitter or LinkedInCheck out my website

Medikabazaar delivered 10,000 oxygen concentrators during COVID-19 and uses AI for precise medical supply stock projections.

Title:

Content: Transforming Hospital Supply Chain with AI and Automation

Medical supplies procurement is the second largest expense which constitutes approximately 1/3rd of a hospital’s Total Cost of Operations (TCO). Technology like AI can give precise stock projections so hospitals can purchase the appropriate quantity of medical equipment, devices, and consumables at the right time. Hospitals can reduce operational expenses in the procurement of medical supplies and manage inventories efficiently. This, in-turn, will make healthcare affordable for the patients.

Vivek Tiwari, Founder and CEO of Medikabazaar elaborates on the need to deploy automation in inventory management in hospitals as it helps to cut costs and bring in financial efficiency by saving on the Total Cost of Operations (TCO) and indirectly result in affordable medical bills for the patients.

How COVID 19 has exacerbated the stress on the healthcare system, causing a supply-demand crunch during an emergency situation. What was your role when the pandemic hit? Impact the pandemic has created in the medical supply chain space?

The outbreak of COVID-19 affected almost every business and healthcare, no matter how badly affected, has been up-front and centre of the world’s response in fighting the pandemic. Initially, there was a pressing need for medical equipment and supplies like ventilators, infrared thermometers, PPE Kits, masks, sanitizers etc., the use of which is now more widespread than before with extremely erratic demand-supply patterns across the country. This led us to create one platform which enrols both suppliers and customers of COVID-19 supplies, so we could aggregate accordingly. We devised the COVID Combat Collaboration Platform which brought together the COVID-19 product buyers, suppliers and experts on a single platform to address the huge demand-supply gap and host relevant and reliable information related to this disease.

During the second wave, when the oxygen crisis arose, we procured, delivered and installed oxygen supply systems like oxygen concentrators across India. As part of Project Breathe, we delivered over 10,000 oxygen concentrators to organisations, corporate and prominent hospitals like CMC Vellore, Apollo Hyderabad and Indore, Motherson and Medicover hospital.

We were involved with every stage of the Covid-19 era, right from incorporating modern testing booths at hospitals, installing beds at government recognised COVID centres, to supporting vaccination with VACCICOOL, our proprietary cold-chain vaccine transportation solution and ICU packages designed for COVID patients (adults and children).

Many healthcare digital platforms are coming up in the B2B space. How have you changed the Indian medical supply chain segments, if you can specify trends and changes you have brought into this segment?

While there are many emerging healthcare B2B digital platforms, we offer much more than just a marketplace in the form of our technological product offerings. There are multiple factors that differentiate us from every other competitor in the market.

Our marketplace is dedicated to making healthcare procurement easier, smarter and more efficient for hospitals and medical establishments, which would in turn help them provide care facilities at better prices for patients. The marketplace started with a few thousand products, but now hosts the largest catalogue of medical, dental and veterinary supplies, consumables, equipment and other devices, running up to more than 700,000 SKUs, serving over 18 countries, more than 200,000 customers.

We have successfully delivered over 500 million units to more than 20,000 pin codes across India and connected over 200,000 medical establishments and healthcare professionals globally.

As for costs we help hospitals unlock savings of up to 30 percent with smart-decision making tools like VPO and the patent-recognised AI-ML based inventory management system VIZI. We identify AI has a emerging technology opportunity that can benefit the businesses and healthcare organisations. We are developing cutting-edge research and technology to leverage these opportunities and help businesses. We are into conducting research, applying AI to products and to new domains, and developing tools to ensure that we leverage technology to transform the industry. VIZI and VPO have led to savings in many hospital chains like Jaslok Hospital, Fortis Hospitals, Wockhardt Hospitals, Sir HN Reliance Foundation Hospital, Apollo Hospitals, Artemis Hospitals and Max Healthcare.

With the help of finance partners, Medikabazaar is assisting healthcare providers set up hospitals with smart and easy payment options like revolving credit, no cost EMI, long term asset financing and more. And with our asset lifecycle management service MBARC, service thousands of equipment with our team of 100+ engineers.

Hospitals procure at cheaper rates, but patients are always charged with more margins. How do you see this?

Although hospitals provide a significant humanitarian service where they cure people from life-threatening diseases, they are also like companies with common operational expenses such as staff salaries, debts, etc. Medical supplies procurement is the second largest expense which constitutes approximately 1/3rd of a hospital’s Total Cost of Operations (TCO).

The reason for such high operational costs in procurement is due to offline supply chain systems which are still utilised by Indian healthcare facilities. Lack of channels for gaining product information, the limited scope of comparing them along with restrained communication lines between manufacturers and hospitals are some of the main limitations of offline procurement.

These disadvantages result in uninformed purchases by hospitals where they end up buying mid-quality supplies at disproportionate prices. This in turn severely affects patient care. Additionally, as hospitals purchase supplies at high prices, patients have to bear expensive medical bills making healthcare unaffordable for many in a country like India.

Automation of medical supplies: How does it help in Total Operational Cost (TOC) of a hospital? Can you explain to us how your procurement platform impacts the operating cost of hospitals, why do you think tier II and III hospitals should adopt online procurement of medical supplies?

Hospitals have an established and conventional procedure to procure their medical supplies where the purchase manager searches and reviews potential vendors. After the vendor is selected, hospitals contact them to inquire about their required supplies, negotiate prices, and then procure them. Such an offline procurement process can be complicated and costly.

The objective of medical establishments should be to make the procurement process qualitative, cost-effective which can allow them to save on their Total Cost of Operations (TCO) and indirectly result in affordable medical bills for the patients.

Since there is a lack of automation in inventory management, hospitals find it difficult to manage their inventories due to an erratic demand of medical devices for patient care.

With the integration of AI in our patented application, VIZI, we provide hospitals with precise stock projections so that they can purchase the appropriate quantity of medical equipment, devices, and consumables at the right time. This way they can reduce their operational expenses in the procurement of medical supplies and also manage their inventories efficiently without having to face excesses, shortages, and expiries in stock.

Our largest online catalogue of medical supplies and equipment that hosts over 700,000 SKUs of medical devices, equipment, and consumables, hospitals can choose their required supplies. With us acting as a single point of purchase, hospitals don’t have to contact multiple vendors and handle numerous quotations which save them valuable time and transactional costs. This way, medical establishments can save significantly in their operational expenses thus in-turn making healthcare affordable for the patients.

In India especially, medical facilities in tier-2, 3 cities, and remote locations can get their supplies via our efficient last-mile delivery, something which fragmented offline distribution systems have failed to achieve. Our online platform also provides flexi-finance options such as zero-cost EMIs and rolling credit limit for easing the payment process for healthcare facilities, thereby ensuring better accessibility and availability of medical supplies in tier-II and III hospitals.

What transformation will UK's CDC group new investment bring into Medikabazaar?

CDC’s investment in Medikabazaar will help to streamline the medical supply chain in India, resulting in improved availability of a wide assortment of medical supplies, transparent pricing and lower search costs for small providers. In turn, such products and services would enable these providers to meet the health needs of smaller groups and communities that live beyond large cities. Currently, about 50 percent of our sales are to smaller hospitals and nursing homes, and around 60 percent of the medical establishments that we serve are based outside metro cities.

The new investment is also helping augment our ability to pre-empt any further threat from another wave of COVID-19. Following the recent launch of our ICU packages for adults and children, CDC’s involvement will accelerate our effort to help medical establishments rapidly augment critical care facilities, in preparation for any furtherpandemics or health emergencies. Over and above their investment, we will also benefit greatly from CDC’s sector expertise to support us in scaling our operation across the country to deliver greater variety of essential medical supplies at affordable cost to more customers.

What are the key technologies trends that are increasingly changing the medical supply chain and how it will help in bridging the accessibility and affordability gap?

Supply chain management is one of the largest expensive business functions for healthcare service providers. One of the most effective ways to manage the healthcare supply chain is by using emerging technologies. Some emerging technologies that can impact the healthcare SCM include Intelligent AI and Analytics, Internet of Thing (IoT), Blockchain, and 3D Printing.

The use of AI in areas such as decision support for traditional inventory management has changed the way healthcare providers used to manage, interpret and analyse the data that they collect from various sources. Data analytics has shifted from descriptive to predictive and prescriptive analytics, which allow them to predict future events and decide the next course of action based on that intelligence.

Internet of Things (IoT)-enabled devices are revolutionising remote monitoring in the healthcare sector. Efficient remote monitoring of patients helps in reducing the length of hospital stays and prevents re-admissions. IoT also has a major impact on reducing healthcare costs significantly and improving treatment outcomes.

Blockchain can help healthcare providers in tracking and tracing the supplies remotely, efficiently and securely. Blockchain can also provide visibility and traceability of products across the value chain – right from the raw material provider to manufacturers to healthcare providers with detailed information about every step, without risks of data tampering.

With the help of 3D printing technology, it will soon be possible to produce products in mass, with the added functionality of adding personalisation. Healthcare is one of the sectors that can immensely benefit by adopting the 3D printing technology for various surgical items. 3D printing technology has the power to streamline the supply chain with mass production for quality care.

Follow and connect with us on , Facebook, Linkedin

Sponsored Stories

      Partners:

Medikabazaar's platform hosts over 700,000 medical device SKUs, reducing hospital operational expenses by up to 30 percent through automation.

VIZI AI-ML based inventory management system will improve India's medical supply chain and availability with CDC's investment.

Predictive analytics and digital supply chain management reduce inventory by 22% and costs by 10-15%.

Title:

Content:   • Thu. Oct 19th, 2023

North East Connected

Hopping Across The North East From Hub To Hub

How Digital Transformation Can Help Increase Profits

ByDave Stopher

Oct 19, 2023

Digital transformation is the strategic integration of digital technologies across all facets of a business, revolutionising its operations and value delivery. It encompasses cloud computing, data analytics, AI, and more.

In today’s hyper-competitive business environment, adaptability and innovation are paramount. According to a survey by McKinsey & Company, 87% of senior business leaders consider digital transformation a top priority for their companies. This underscores its widespread recognition.

Embracing digital transformation isn’t just a modernisation effort; it’s a strategic shift directly impacting a company’s financial bottom line. This article delineates how businesses, particularly those in the software and app development sectors, can leverage digital transformation for substantial profit growth.

Top 18 Ways Digital Transformation Can Increase a Company’s Profits

Automation of Repetitive Tasks

Implementing digital tools enables the automation of mundane tasks, leading to a 20% improvement in operational efficiency. A study by Salesforce, a prominent software company, underscores this significant enhancement.

Optimisation of Workflows

Digital transformation empowers businesses to streamline workflows, resulting in a 30% increase in process efficiency. A comprehensive report by a renowned consulting company, Deloitte, supports this finding.

Real-time Data Analysis and Decision-making

By utilising digital analytics, companies can make real-time data-driven decisions. A study by Gartner, a leading analytics firm, reports that businesses employing real-time analytics are over twice as likely to experience marked improvements in decision-making.

Personalisation and Customization

Digital channels enable businesses to offer highly personalised experiences, leading to a 15% increase in customer satisfaction.

Multi-channel Engagement

Companies leveraging digital transformation can engage customers across diverse channels, resulting in an 89% customer retention rate. This statistic is derived from the Harvard Business Review research emphasising the importance of omnichannel engagement strategies.

Feedback Loops and Continuous Improvement

Digital platforms facilitate real-time feedback loops, allowing businesses to respond to customer feedback swiftly. According to Forrester Research, a customer experience research firm, this leads to a 10% increase in customer retention rates.

Globalisation through Digital Platforms

Digital transformation transcends geographical boundaries, enabling businesses to reach a global audience. The World Trade Organization highlights that digitally enabled small businesses are 22% more likely to experience export growth.

Targeting Niche Markets

Through precise digital marketing strategies, businesses can target niche markets, resulting in a 14.6% increase in conversion rates. A study from the Content Marketing Institute, a leading digital marketing agency, supports this finding.

Reaching Mobile-First Consumers

The ubiquity of mobile devices has created a vast market of mobile-first consumers. Businesses catering to this trend can tap into a projected £3.56 trillion global mobile commerce market by 2023, as forecasted by GSMA, a prominent mobile industry association. An app development company can help a business carve out a spot in the market faster by developing a robust mobile application.

Harnessing Big Data Analytics

Big data analytics provides invaluable insights into customer behaviour and market trends. SAS, a leading data analytics firm, reveals that big data analytics companies are 23 times more likely to outperform competitors in customer acquisition.

Predictive Analytics for Demand Forecasting

Predictive analytics enables businesses to forecast demand with greater accuracy. A report by Dresner Advisory Services, a renowned business intelligence firm, states that companies employing predictive analytics experience a 22% reduction in excess inventory.

Market Trend Analysis and Competitive Intelligence

Digital tools empower businesses to stay ahead of market trends and gain competitive intelligence. A report by MarketResearch.com indicates that companies with access to real-time market intelligence achieve, on average, 20% higher revenue growth.

Cloud Computing and Infrastructure Efficiency

Transitioning to cloud-based solutions can significantly reduce IT costs. A study by Amazon Web Services (AWS), a leading cloud services provider, found that businesses that migrate to the cloud experience an average cost reduction of 15-20%.

Digital Supply Chain Management

Digital transformation enables more efficient supply chain operations. According to a report by the SCM World, a renowned supply chain management institute, businesses implementing digital supply chain solutions experience an average cost reduction of 10-15%.

Remote Workforce and Collaboration Tools

Digital tools facilitate remote work, reducing the need for physical office space. A study by Mercer, a prominent HR consulting firm, found that companies with a remote workforce save an average of £8,000 per employee annually.

Rapid Prototyping and Iterative Development

Digital transformation fosters a culture of rapid prototyping and iterative development, allowing businesses to market new products and services faster. A report by PwC, a leading innovation research institute, found that companies that adopt agile methodologies experience a 70% increase in project success rates.

Embracing Emerging Technologies (AI, IoT, Blockchain)

By embracing emerging technologies, businesses can gain a competitive edge. A survey by Gartner, a renowned technology research firm, revealed that companies investing in AI, IoT, and blockchain technologies report an average revenue increase of 17%.

Adapting to Changing Market Dynamics

Digital transformation enables businesses to adapt quickly to changing market conditions. Research by McKinsey & Company shows that companies that are agile in responding to market changes experience, on average, a 20% higher profitability.

Conclusion

Digital transformation offers many benefits, from increased operational efficiency to enhanced customer experiences and expanded market reach. These advantages are particularly pronounced for businesses in the software and app development sectors.

Businesses that proactively harness digital technologies are poised for sustained success and profitability. As technology continues to advance, new avenues for digital transformation will emerge. Staying ahead of these trends will be pivotal for businesses seeking a competitive edge in the ever-evolving market.

In conclusion, the impact of digital transformation on profit growth is profound. It is a strategic imperative that businesses, especially in the software and app development sectors, must wholeheartedly embrace. Through streamlining processes, enhancing customer experiences, expanding market reach, leveraging data-driven insights, reducing costs, fostering innovation, and measuring ROI, businesses can unlock the full potential of digital transformation and pave the way for sustained profitability.

Big data analytics and digital transformation aid customer acquisition and increase operational efficiency by 20%.

Automation and digital tools improve efficiency by 20% and streamline workflows by 30%.

Automation and digital tools improve efficiency by 20% and streamline workflows by 30%.

Automation and digital tools improve efficiency by 20% and streamline workflows by 30%.